ESSENTIAL - ION Graphic Design Works · standardized Essential Medicines List can meet end users’ requirements and help rationalizing the purchase and distribution of medicines,

ESSENTIALMEDICINES LIST

Department of Health Government of Balochistan

ESSENTIAL MEDICINES LIST

October 2014

This publication was produced for review by the U.S. Agency for International Development. It was prepared by the USAID | DELIVER PROJECT, Task Order 4.

The authors’ views expressed in this publication do not necessarily reflect the views of the U.S. Agency for International Development or the United States Government.

ESSENTIAL MEDICINES LIST | 3

CONTENTS

Acronyms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5

Symbols and Terms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7

Foreword . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9

Acknowledgment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11

Essential Medicines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13

Using the Essential Medicines List . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19

References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23

EML for BHUs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25

EML for RHCs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37

EML for THQs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53

EML for DHQs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71

Figures

1. Development of Essential Medicines List . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15

2. Percentage of Total Deaths for All Ages in Pakistan . . . . . . . . . . . . . . . . . . . . . . 17

3. Structure of Provincial Health System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18

Table

1. Medicines with Age or Weight Restrictions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21

Recommended Citation The Department of Health, Government of Balochistan, Pakistan. 2014. Essential Medicines List. Islamabad, Pakistan: USAID | DELIVER PROJECT, Task Order 4, for the Department of Health, Government of Balochistan, Pakistan.

Abstract The Department of Health, Government of Balochistan, formally approached the USAID | DELIVER PROJECT in 2012, seeking technical support to develop EMLs for the primary- and secondary-level health facilities in the province. The project quickly mobilized its resources to respond to this request; they developed customized EMLs after detailed consultation with all stakeholders, including health and medical professionals from the WHO (Pakistan office), as well as the districts. The Department of Health, Government of Balochistan, is pleased to announce the first-ever province-specific EMLs for primary- and secondary-level health facilities; they meet WHO standards and WHO Pakistan has endorsed them.

USAID | DELIVER PROJECT/IslamabadHouse No 253 C Street 23 Sector E 7 Islamabad, Pakistan Phone: 92.051.2655425 Fax: 92.051.2655427 Email: [email protected] Internet: deliver.jsi.com


ACRONYMS

BOD burden of disease

CDC Centers for Disease Control and Prevention

DOH Department of Health

DRAP Drug Regulatory Authority of Pakistan

EDL Essential Drugs List

EML Essential Medicines List

ENT ear, nose, throat

EPI Expanded Programme on Immunization

GIT gastrointestinal

HCl hydrochloride

HSRU Health Sector Reform Unit

IDU injecting drug user

INN international non-proprietary names

IU international unit

MDR multidrug-resistance

MIU million international units

MOH Ministry of Health

ESSENTIAL MEDICINES LIST | 7 6 | ESSENTIAL MEDICINES LIST

MSW male sex worker

NCD non-communicable disease

NEML National Essential Medicines List

PIH pregnancy induced hypertension

PVRV purified vero cell rabies vaccine

BPPR Balochistan Public Procurement Rules

UNICEF United Nations Children’s Fund

USAID U.S. Agency for International Development

WHO World Health Organization

w/v weight by volume

SYMBOLS AND TERMS

Note: The drugs listed in this medicines list are generic drugs; therefore, the names of the medicines are always written in lowercase letters.

The following symbols are used throughout this list of medicines:

ª Primarily indicates similar clinical performance within a pharmacological class.

ò Indicates that the medicine has an age or weight restriction.

© Signifies a specific indication for restricting its use for children.

ACRONYMS


FOREWORD

The right to health is a fundamental human right and provision of essential medicines is one of the essential components of primary health care. A standardized Essential Medicines List can meet end users’ requirements

and help rationalizing the purchase and distribution of medicines, thereby, reducing costs of the healthcare. .

The World Health Organization (WHO) defines Essential Medicines as “those that satisfy the priority health care needs of the population”. They are intended to be available within the context of functioning health systems at all times in adequate amounts, in the appropriate dosage forms, with assured quality, and at a price the individual and the community can afford.

Before 2011, it was the responsibility of the Federal Ministry of Health to develop and update Essential Medicines Lists (EMLs) while provinces were maintaining medicines procurement lists based on their field requirements. However, after the 18th Constitutional Amendment in June 2011, when all administrative and financial powers were devolved to the provinces, it was acknowledged by the Department of Health, Government of Balochistan, that there should be segregated lists of essential medicines for each facility level.

The Department of Health, Government of Balochistan, formally approached USAID | DELIVER PROJECT in 2012, for seeking technical support to develop EMLs for the primary and secondary level health facilities in the province. The Project quickly mobilized its resources to respond this request and developed customized EMLs after detailed consultation with all stakeholders, including health and medical professionals from the WHO (Pakistan office) as well as districts. The Department of Health, Government of Balochistan, is pleased to announce the


first ever province-specific EMLs for primary and secondary level health facilities that meet WHO standards and have also been endorsed by WHO Pakistan. The EMLs have been distributed among all stakeholders up to districts level for implementation.

The Department of Health will convene a provincial committee in Balochistan with a proportionate representation of health and medical professionals. This committee will be reviewing and updating the EMLs regularly based on end users’ requirements and an updated version will be available at http://www.balochistan.gov.pk/health.

I would like to express my gratitude to USAID/Pakistan for providing the support through USAID | DELIVER PROJECT for development of province-specific standard EMLs for Balochistan. I am also grateful to the WHO/Pakistan for extending their technical support in the accomplishment of the EMLs. Their concurrent support will contribute to ensuring transparency and value for money in procurement, enhancing performance of health professionals, and ensuring availability of quality medicines for the people of Balochistan.

Secretary, Department of Health Government of Balochistan

ACKNOWLEDGMENT

The Essential Medicines Lists (EMLs) have been developed for primary and secondary level healthcare facilities of the Department of Health (DOH), Government of Balochistan, with the technical and financial

support of United State Agency for International Development (USAID)-funded USAID | DELIVER PROJECT, and with the technical guidance of the World Health Organization (WHO) Pakistan Office. Moreover, the health and medical professionals from district health offices and public sector health institutions of Balochistan have also contributed and provided valuable inputs in finalizing the EMLs.

I would like to express my deepest appreciation to all relevant public sector stakeholders, development partners, health specialists and medical professionals from WHO/Pakistan for reviewing, contributing, guiding and supporting the development of the EMLs for primary and secondary healthcare facilities of Balochistan.

The DOH highly appreciates the auspicious and productive support of USAID/Pakistan towards strengthening the health sector of the Balochistan province. I would like to thank Mr. Randolph Augustin, Director, Health Office, USAID | Pakistan and Mr. Khalid Saeed Bukhari of WHO Pakistan for their leadership and coordinated support enabling the USAID | DELIVER PROJECT to successfully produce the EMLs.

We also wish to appreciate Dr. Muhammad Tariq, Country Director, USAID | DELIVER PROJECT Pakistan for his leadership role and his dedicated team for their devoted efforts and support provided in developing the EMLs.

Director General Health Services, Department of Health Government of Balochistan

FOREWORD


ESSENTIAL MEDICINES

Medicines have a major role in protecting, maintaining, and restoring health. Policymakers and departments implementing health activities and programs are responsible for providing appropriate quality

medicines, in adequate quantities, at reasonable prices.

However, to ensure equitable access to quality medicines and to promote their rational use, developing countries still face challenges—even though governments, development agencies, and the World Health Organization (WHO) continue their efforts. Recently, the reforms in health sector financing, globalization, and economic recessions have shown improved access to essential medicines.

The publication, WHO Model List of Essential Medicines (WHO 2011b), is a guide for developing national and institutional essential medicines lists. This model list is regularly revised.

Essential medicines are—

• intended to satisfy the priority healthcare needs of the population

• selected with regard to disease prevalence, evidence on efficacy and safety, and comparative cost effectiveness

• intended to be available within the context of functioning health systems, at all times; in adequate amounts, in appropriate dosage forms, with assured quality, and at a price the individual and the community can afford


• one of the most cost-effective elements in modern healthcare; their potential health impact is enormous.

The WHO list is regularly updated with a selection of medicines that reflect new therapeutic options and changing therapeutic needs. It helps to ensure drug quality and to continue developing better medicines—medicines for emerging diseases and medicines to meet changing resistance patterns.

WHAT ARE ESSENTIAL MEDICINES?Since 2002, essential medicines have been defined as “those that satisfy the priority health-care needs of the population. They are selected with due regard to public health relevance, evidence on efficacy and safety, and comparative cost-effectiveness. Essential medicines are intended to be available within the context of functioning health systems at all times in adequate amounts, in the appropriate dosage forms, with assured quality and adequate information, and at a price the individual and the community can afford. The implementation of the concept of essential medicines is intended to be flexible and adaptable to many different situations; exactly which medicines are regarded as essential remains a national responsibility.” This definition evolved from the first definition in 1977 (WHO 1977), which was adopted in the Alma-Ata Declaration of 1978 (WHO 1978). The main change has been the selection process—from an experts-based approach to an evidence-based approach.

An EML includes a limited number of carefully selected medicines. These lists have been published as formularies and institutional lists of medicines, which are made available to health facilities and health workers. The list may not always be called an EML; but, whatever name is used, they all serve the same function. EMLs have been one cornerstone of public health delivery and the basis for efforts to ensure consistent medicine supply and management. It is an important strategy for improving access to and use of medicines, especially for the vulnerable segment of a population. Furthermore, an EML can be an advocacy tool to help countries spend their limited resources on the medicines that are most needed and that offer the best value for the money.

WHO recommends the following process to develop a national EML (see figure 1).

Figure 1 . Development of Essential Medicines List

PAKISTAN NATIONAL ESSENTIAL MEDICINES LISTTo address the disease burden in Pakistan, as noted above, the National Essential Medicines (Drugs) List (NEML) of Pakistan was first prepared in 1994, after consultations with experts in the field. The list was reviewed in 1995, 2000, 2003, and 2007. The former Federal Ministry of Health (MOH) previously published and disseminated this list to healthcare professionals as part of an

Disease Burden

Evidence-based Standard Treatment Guidlines (STGs)

By Level

(EML)

Essential Medicines List

ESSENTIAL MEDICINES ESSENTIAL MEDICINES


effort to increase the acceptability of the concept, as envisaged in the National Drug Policy. The former MOH expected the provincial health departments and the local health authorities to procure the drugs recommended on the list. Although the list was not followed exactly in practice, the concept remains the best cost-effective mechanism for the public procurement of drugs; therefore, using the EML should be encouraged.

Recently the Drug Regulatory Authority of Pakistan (DRAP), in collaboration with WHO Pakistan, has prepared and published the National EML 2014.

WHO discourages using the term Essential Drugs Lists (EDL) because the word Drugs is also commonly used for narcotics and other stimulant drugs. Therefore, WHO recommends using the title Essential Medicines List (EML).

PAKISTAN FACING A DOUBLE BURDEN OF DISEASEThe burden of disease (BOD) in Pakistan is dominated by communicable diseases, reproductive health problems, and malnutrition; which, collectively, account for about 50 percent of the total (WHO 2013). This includes a high maternal mortality ratio (276/100,000 live births); low antenatal care coverage (61 percent); frequent complications of pregnancy and child birth; low family planning coverage (30 percent); and a high ratio of children under 5 years, infant, and neonatal mortality (94, 78, and 54/1,000 live births, respectively). Malnutrition in the young is an underlying cause of more than 50 percent of the deaths—one-fifth of newborns have low birth weight and 38 percent of children under 5 years of age are underweight. These health issues are aggravated by a low exclusive breastfeeding rate for infants’ under 6 months (37 percent of children) and low vaccination coverage (47 percent). Added to this burden are non-communicable diseases (NCD), including cardiovascular disease, diabetes, cancer, injuries, and neuro-psychiatric disorders. This double BOD is a major challenge in the health sector of Pakistan. Respiratory infections and diarrheal diseases are still the major fatal diseases in Pakistan, particularly for children under 5. Pakistan is the second country (after India) in Southeast Asia that is moving toward a concentrated HIV and AIDS epidemic stage for groups like injecting drug users (IDUs) and male sex workers (MSWs). The percentage

mortality rates for Pakistan for 2008 estimates are represented in figure 2 (WHO 2011a).

Figure 2 . Percentage of Total Deaths for All Ages in Pakistan

ACTIVITIES AND PROCESS ADOPTED TO DEVELOP EMLSExtensive Internet research produced data and other available information, including websites for WHO, United Nations Children’s Fund (UNICEF), Centers for Disease Control and Prevention (CDC), Department of Health (DOH) Balochistan, Balochistan Health Sector Reform Unit (HSRU), and many other relevant resource organizations. To access information on available EMLs and procurement lists, consultative meetings were held with the WHO Pakistan

Communicable, Material, Perinatal, and Nutritional Conditions

46%

Respiratory Diseases 5%

Injuries 8%

CVD 25%

Cancers 7%

Diabetes 1%

Other NCDs 8%

ESSENTIAL MEDICINES ESSENTIAL MEDICINES


team, as well as the provincial- and district–health officials. All the material/information collected was reviewed; a completed situation analysis identified the gaps and challenges.

After completing these steps, recommended procurement lists for essential drugs/medicines were developed for each primary- and secondary-level healthcare facility for the Department of Health, Balochistan. These lists are based on the WHO Model List of Essential Medicines, WHO treatment guidelines and feedback, and observations from visits to health facilities. The draft lists were shared with WHO Pakistan; after several consultations, a final draft was endorsed by WHO, which was then shared with the provincial- and district–health officials of Balochistan in a consultative workshop (see figure 3). The recommendations from the workshop were incorporated and the Balochistan Health Department approved the lists for implementation across the province.

Figure 3 . Structure of Provincial Health System

Referrals Referrals

Provincial Department

of Health

DHOs District Health

Officers

Civil Surgeons DHQ Hospitals

Tertiary Hospitals

BHUs RHUsTHQ

Hospitals

R e f e r r a l s

USING THE ESSENTIAL MEDICINES LIST

Use the EML for standardized procurement. The EML uses the international non-proprietary names (INN) classification, which is the official shortened scientific name or generic name of the medicine,

based on the active ingredient. Using the INN reduces the risk of duplication, confusion, or errors in identifying a product. For example, cotrimoxazole—the official or generic name—is easier to recognize and remember than the range of alternatives, such as Septran, Bactrim, etc.; and it avoids mistakes in prescribing, dispensing, and ordering. Generic drugs/medicines are also usually much cheaper than proprietary drugs. Rule 13 of Balochistan Public Procurement Rules (BPPR) 2013 also prohibits the use of proprietary or brand names.

EMLs help simplify the quantification of drug requirements and the training for those prescribing and dispensing drugs. If only a limited number of drugs are used, health workers will be more familiar with indications, dosages, side effects, and contraindications.

ESSENTIAL MEDICINES


EXPLANATORY NOTES

The segregated core lists presents the list of minimum medicine needs for a basic healthcare system; it lists the most efficacious, safe, and cost-effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance and the potential for safe and cost-effective treatment.

ª The square box ª symbol primarily indicates similar clinical performance within a pharmacological class . The listed medicines are examples of the class with the best evidence for effectiveness and safety . In some cases, this may be the first medicine licensed for marketing; in other cases, subsequently licensed compounds may be safer or more effective . If the efficacy and safety data are the same, the listed medicine is the one that is generally available at the lowest price, based on international drug price information sources . Not all square boxes are applicable to medicine selection for children . Therapeutic equivalence is only indicated based on the reviews of efficacy and safety and when consistent with WHO clinical guidelines .

ò The ò symbol indicates an age or weight restriction for the medicine; see table 1 for details for each medicine .

© The © symbol signifies a specific indication for restricting its use for children .

An entry on the EML carries no assurance of pharmaceutical quality. It is the responsibility of the relevant procurement authority to ensure that each product is of appropriate pharmaceutical quality (including stability); and that, when relevant, different products are interchangeable.

Medicines and dosage forms are listed in alphabetical order within each section; one form is not preferred over another. Consult standard treatment guidelines for information on appropriate dosage forms.

Table 1 . Medicines with Age or Weight Restrictions

atazanavir >25 kg

atropine >3 months

benzyl benzoate >2 years

betamethasone topical preparations hydrocortisone preferred for neonates

cefazolin >1 month

ceftriaxone >41 weeks corrected gestational age

chlorphenamine >1 year

diloxanide >25 kg

doxycycline >8 years (except for serious infections, e .g ., cholera)

efavirenz >3 years or >10 kg

emtricitabine >3 months

fluoxetine >8 years

ibuprofen >3 months (except IV form for patent ductus arteriosus)

mefloquine >5 kg or >3 months

metoclopramide not for neonates

ondansetron >1 month

saquinavir >25 kg

silver sulfadiazine >2 months

tetracaine not for preterm neonates

trimethoprim >6 months

xylometazoline >3 months

USING THE ESSENTIAL MEDICINES LISTUSING THE ESSENTIAL MEDICINES LIST


REFERENCES

World Health Organization (WHO). 1978. Declaration of Alma-Ata International Conference on Primary Health Care, Alma-Ata, USSR, 6-12 September 1978. Geneva: WHO. Available at http://www.who.int/publications/almaata_declaration_en.pdf?ua=1 (accessed October 21, 2014)

World Health Organization (WHO). 2002. Promoting Rational Use of Medicines: Core Components - WHO Policy Perspectives on Medicines, No. 005, September 2002. Available from: http://apps.who.int/medicinedocs/en/d/Jh3011e/2.html (accessed October 21, 2014)

World Health Organization (WHO). 2011a. NCD Country Profiles. Geneva: WHO. Available at http://www.who.int/nmh/countries/pak_en.pdf (accessed October 21, 2014)

World Health Organization (WHO). 2011b. WHO Model List of Essential Medicines. Geneva: WHO.

World Health Organization (WHO). 2013. Pakistan: Country Cooperation Strategy at a glance. Geneva: WHO. Available at http://www.who.int/countryfocus (accessed October 21, 2014)


EML FOR BHUs





EML FOR BHUs

BH

Us

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

A

Ane

sthe

tics

loca

l 1

lidoc

aine

(hy

droc

hlor

ide)ª

vial

/am

poul

e2%

w/v

(10

ml)

topi

cal

2% g

el (

15gm

)

B

Ana

lges

ics/

NSA

IDs

2ac

etyl

salic

ylic

aci

d (d

ispe

rsib

le/

solu

ble)

tabl

et10

0mg

to 5

00m

g

3ac

etyl

salic

ylic

aci

dsu

ppos

itory

50m

g to

150

mg

4di

clof

enac

(so

dium

)am

pule

75m

g in

3m

l

5ib

upro

fenò

tabl

et20

0mg,

400m

g

syru

p20

0mg/

5ml

6pa

race

tam

ol

tabl

et50

0mg

syru

p12

5mg/

5ml

supp

osito

ry10

0mg

C

Ant

i-Alle

rgic

s an

d m

edic

ines

use

d in

an

aphy

laxi

s7

chlo

rphe

nira

min

e

(hyd

roge

n m

alea

te)ò

ª

tabl

et4m

g

syru

p©2 .

5mg/

5ml

inje

ctio

n10

mg/

ml

8de

xam

etha

sone

(di

sodi

um

phos

phat

e)in

ject

ion

4mg/

ml

9ep

inep

hrin

e (a

dren

alin

e)am

pule

1mg/

ml

10hy

droc

ortis

one

(sod

ium

su

ccin

ate)

inje

ctio

n10

0mg,

250m

g

11pr

edni

solo

neª

tabl

et5m

g

12lo

ratid

ine

tabl

et10

mg

syru

p1m

g/m

l


EML FOR BHUsEML FOR BHUs

BH

Us

BH

Us

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

A

NT

I-IN

FEC

TIV

ES

D

Ant

ibio

tics/

an

timic

robi

als

13

amox

icill

in (

trih

ydra

te)

caps

ule/

tab

let

250m

g, 50

0mg

(pre

fera

bly

disp

ersi

ble

tabl

et)

syru

p©12

5mg,

250m

g/5m

l

inje

ctio

n25

0mg,

500m

g

14am

pici

llin

(as

sodi

um s

alt)

in

ject

ion

500m

g an

d 1g

15ci

profl

oxac

in (h

ydro

chlo

ride

)ªta

blet

250m

g, 50

0mg

16co

trim

oxaz

oleò

tabl

et©

400m

g +

80m

g

(sul

fam

etho

xazo

le +

tr

imet

hopr

im)

syru

p©20

0mg

+ 4

0mg/

5ml

17ª

met

roni

dazo

le

(ben

zoat

e)

tabl

et20

0mg,

400m

g

syru

p20

0mg/

5ml

E

Ant

i-Hel

min

thic

18m

eben

dazo

le (

chew

able

)ta

blet

500m

g

(with

cau

tion,

onl

y fo

r ad

ults

)

syru

p10

0mg/

5ml

F

Ant

i-Fun

gal

19ny

stat

in

tabl

et50

0,00

0 IU

drop

s©10

0,00

0 IU

/ml

pess

ary

100

000

IU

20cl

otri

maz

ole

vagi

nal c

ream

1%

vagi

nal t

able

t10

0mg

and

500m

g

G

Ant

i-Tub

ercu

losi

s m

edic

ines

21et

ham

buto

lta

blet

400m

g

oral

liqu

id©

25m

g/m

l

As p

er T

B co

ntro

l pro

gram

gu

idel

ines

22is

onia

zid

tabl

et/s

yrup

©50

mg,

100m

g, 30

0mg

23py

razi

nam

ide

tabl

et50

0mg

24ri

fam

pici

nca

psul

e/sy

rup©

150m

g, 30

0mg,

450m

g, 60

0mg

25st

rept

omyc

inin

ject

ion

1gm

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

26et

ham

buto

l + is

onia

zid

tabl

et40

0mg

+ 1

50m

g

27is

onia

zid

+ r

ifam

pici

nta

blet

75m

g +

150

mg;

150m

g +

300

mg

28is

onia

zid

+ p

yraz

inam

ide

+

rifa

mpi

cin

tabl

et75

mg

+ 4

00m

g +

150

mg

29ri

fam

pici

n +

ison

iazi

d +

py

razi

nam

ide

+ e

tham

buto

lta

blet

150m

g +

75m

g +

40

0mg

+ 2

75m

g

30et

ham

buto

l + is

onia

zid

+

rifa

mpi

cin

tabl

et27

5mg

+ 7

5mg

+ 1

50m

g

H

Ant

imal

aria

l31

chlo

roqu

ine

(pho

spha

te o

r su

lfate

)ta

blet

150m

g

For

vivax

32pr

imaq

uine

(di

phos

phat

e)ta

blet

15m

g

For

falci

paru

m

33

arte

suna

te +

sul

phad

oxin

e an

d py

rim

etha

min

eta

blet

co-b

liste

r of

(6

+ 2

) ta

blet

—tw

o la

rge

tabl

ets,

each

has

sul

fado

xine

50

0mg

U .S

.P . +

pyr

imet

ham

ine

25m

g U

.S .P

—an

d si

x sm

all t

able

t, ea

ch

cont

ains

art

esun

ate

50m

g U

.S .P .

To b

e us

ed in

com

bina

tion

(co-

blist

er)

arte

suna

te +

sul

phad

oxin

e an

d py

rim

etha

min

eta

blet

co-b

liste

r of

(6

+ 3

) ta

blet

—th

ree

larg

e ta

blet

s, ea

ch h

as s

ulfa

doxi

ne

500m

g U

.S .P .

+ p

yrim

etha

min

e 25

mg

U .S

.P .—

six

smal

l tab

let,

each

co

ntai

ns a

rtes

unat

e 10

0mg

U .S

.P .

34ar

tesu

nate

tabl

et50

mg

I A

nti-D

iabe

tics

35gl

iben

clam

ide

tabl

et5m

g

36m

etfo

rmin

(hy

droc

hlor

ide)

tabl

et50

0mg

37in

sulin

reg

ular

inje

ctio

n10

0 IU

/ml

38in

sulin

com

pin

ject

ion

30%

+ 7

0% w

/v



BH

Us

BH

Us

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

J C

ardi

ovas

cula

r m

edic

ines

39fu

rose

mid

eªta

blet

20m

g, 40

mg

inje

ctio

n10

mg

40gl

ycer

yl t

rini

trat

esu

blin

gual

500m

cg

41m

ethy

ldop

ata

blet

250m

g

42en

alap

ril (

mal

eate

)ta

blet

5mg,

10m

g

K

Gas

troi

ntes

tinal

(G

IT)

med

icin

es43

hyos

cine

(bu

tylb

rom

ide)

inje

ctio

n20

mg/

ml

tabl

ets

10m

g

44ph

loro

gluc

inol

tabl

ets

phlo

rogl

ucin

ol 8

0mg

+

trim

ethy

lphl

orog

luci

nol 8

0mg

45m

etoc

lopr

amid

e

(hyd

roch

lori

de)ò

tabl

ets

10m

g

syru

p5m

g/5m

l

inje

ctio

n5m

g/m

l

46om

epra

zoleª

caps

ules

10m

g, 20

mg,

40m

g

47ra

nitid

ine

inje

ctio

n25

mg/

ml i

n 2m

l

48al

umin

ium

hyd

roxi

de +

m

agne

sium

tri

silic

ate

tabl

ets

250m

g +

500

mg

Reco

mm

ende

d in

co

mbi

natio

n w

ith z

inc

sulp

hate

20m

g di

sper

sible

ta

blet

for

acut

e di

arrh

ea49

OR

S (lo

w o

smol

arity

)Sa

chet

dry

mix

ture

(lo

w o

smol

arity

fo

rmul

a) in

sac

het

for

1 lit

er o

f so

lutio

n, e

ach

sach

et c

onta

ins

gluc

ose

anhy

drou

s 13

.5gm

B .P .

, tr

isod

ium

citr

ate

dihy

drat

e 2 .

9gm

B .

P . po

tass

ium

chl

orid

e1 .5

gm B

.P .,

sodi

um c

hlor

ide

2 .6g

m B

.P .

50

glyc

erin

supp

osito

ry

LR

espi

rato

ry m

edic

ines

51sa

lbut

amol

(su

lfate

)ªta

blet

2 an

d 4m

g

solu

tion

5mg/

ml f

or n

ebul

izer

52am

inop

hylli

nein

ject

ion

25m

g/m

l

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

M

Mis

cella

neou

s53

atro

pine

(su

lfate

)òam

pule

1mg

in 1

ml

54ch

arco

al a

ctiv

ated

pow

der

55di

azep

amin

ject

ion

10m

g

gel o

r re

ctal

sol

utio

ns5m

g/m

l in

0 .5m

l; 2m

l; 4-

ml

For

ecle

mps

ia o

nly

56m

agne

sium

sul

phat

ein

ject

ion

500m

g/m

l

57na

loxo

ne (

hydr

ochl

orid

e)in

ject

ion

400m

cg in

1m

l

58ox

ygen

con

cent

rato

r/cy

linde

r

N

Oph

thal

mic

/EN

T59

boro

glyc

erin

eea

r dr

ops

(o

nly

for

wax

rem

ovin

g)40

.00%

60po

lym

yxin

B s

ulph

ate

+

ligno

cain

eea

r dr

ops

each

ml c

onta

ins

poly

myx

in

B (s

ulph

ate)

:100

0IU

/m

l,Lig

noca

ine:

50m

g/m

l]; 5

ml p

last

ic

bott

le

61ch

lora

mph

enic

ol

eye

drop

s1%

w/v

, 0 .5

% w

/v

62ge

ntam

icin

(su

lfate

)ey

e dr

ops

0 .30

%

63po

lym

yxin

B (

sulp

hate

) +

ba

citr

acin

zin

cey

e oi

ntm

ent

10,0

00 IU

/g +

500

IU/g

O

I/V in

fusi

ons

64de

xtro

se +

sal

ine

infu

sion

5% +

0 .9

% w

/v

Plas

ma

subs

titut

es65

gluc

ose/

dext

rose

infu

sion

5%,1

0%

66no

rmal

sal

ine

infu

sion

0 .9%

67R

inge

r la

ctat

ein

fusi

on

infu

sion

1,00

0ml c

onta

ins

calc

ium

ch

lori

de 0

.2gm

U .S

.P .; p

otas

sium

ch

lori

de 0

.3gm

U .S

.P .; s

odiu

m

chlo

ride

6gm

U .S

.P .; 3

.1gm

sod

ium

la

ctat

e U

.S .P .

, ste

rile

wat

er fo

r in

ject

ion

1,00

0ml (

q .s .

),1,0

00m

l co

llaps

ible

pla

stic

bot

tle

68w

ater

for

inje

ctio

nam

pule

5ml a

nd 1

0ml



BH

Us

BH

Us

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

PV

itam

ins

and

min

eral

s69

asco

rbic

aci

dta

blet

50m

g, 10

0mg,

500m

g

Mic

ronu

trie

nts

70ca

lciu

m g

luco

nate

inje

ctio

n10

0mg/

ml i

n 10

ml

71ca

lciu

m la

ctat

eta

blet

500m

g, 1g

m

72er

goca

lcife

rol (

vita

min

D)ª

tabl

et1 .

25m

g (5

0,00

0 IU

)

73fe

rrou

s sa

lt (fu

mer

ate)

tabl

eteq

uiva

lent

to

60m

g ir

on

syru

peq

uiva

lent

to

25m

g/m

l iro

n

74fo

lic a

cid

tabl

et0 .

5mg,

1mg,

and

5mg

75fe

rrou

s sa

lt +

folic

aci

dta

blet

(D

RA

P ap

prov

ed)

tabl

et, e

quiv

alen

t to

60m

g ir

on +

40

0mcg

folic

aci

d

76m

ultip

le m

icro

nutr

ient

ssa

chet

UN

ICEF

app

rove

d

77re

tinol

(vi

tam

in A

)ta

blet

/ cap

sule

50,0

00 IU

; 100

,000

IU; 2

00,0

00 IU

(a

s pa

lmita

te)

78zi

nc s

ulph

ate

disp

ersi

ble

tabl

et20

mg

79B

com

plex

tabl

etD

RA

P ap

prov

ed

80m

ultiv

itam

ins

tabl

etD

RA

P ap

prov

ed

Q

Der

mat

olog

ical

s81

benz

yl b

enzo

ateò

ªlo

tion

5%, 2

5%

82ca

lam

ineª

lotio

n15

%

83hy

droc

ortis

oneª

crea

m1%

84po

lym

yxin

B (

sulp

hate

) +

ba

citr

acin

zin

coi

ntm

ent

10,0

00 IU

/g +

500

IU/g

85

silv

er s

ulph

adia

zineò

crea

m1%

R

Oxy

toci

c m

edic

ines

86er

gom

etri

ne (

hydr

ogen

mal

eate

)ªin

ject

ion

200m

cg in

1m

l

87m

isop

rost

olta

blet

200m

cg

88ox

ytoc

inin

ject

ion

10 IU

in 1

-ml

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

S

Con

trac

eptiv

es

89co

ndom

s

90et

hyny

lest

radi

olª

+

nore

this

tero

neª

C

O p

ills

35m

cg +

1m

g

91le

vono

rges

trelª

PO

pill

s30

mcg

92co

pper

T/m

ultil

oad

IUC

D

93 m

edro

xypr

oges

tero

ne a

ceta

te

(DM

PA)

inje

ctio

n15

0mg

/1m

l

94no

reth

iste

rone

ena

ntat

ein

ject

ion

200m

g/m

l in

1ml

T

Vacc

ines

and

ser

a95

BCG

vac

cine

WH

O-a

ppro

ved/

as p

er

natio

nal E

PI p

rogr

am

96D

PT v

acci

ne

97he

patit

is v

acci

ne

98m

easl

es v

acci

ne

99po

lio v

acci

ne

(OPV

tri

vale

nt)/

IPV

oral

/ inj

ectio

n

100

pent

aval

ent

vacc

ine

101

pneu

moc

occa

l vac

cine

102

teta

nus

toxo

id

103

anti-

rabi

es v

acci

ne (

PVRV

)si

ngle

-dos

e vi

al

104

anti-

snak

e ve

nom

ser

um



BH

Us

BH

Us

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

U

Ant

isep

tics/

di

sinf

ecta

nts

105

povi

done

-iodi

neso

lutio

n10

% w

/v

Onl

y ch

lorin

e-ba

sed

com

poun

d in

sta

ble

dry

gran

ular

form

106

halo

gena

ted

natr

ium

ph

osph

ate

pow

der

100g

ms

107

chlo

rine

-bas

e co

mpo

und

pow

der

(0 .1

% a

vaila

ble

chlo

rine

)

for

solu

tion

108

chlo

rhex

idin

e +

cet

erim

ide

solu

tion

1 .5%

w/v

+ 1

5% w

/v

Ant

isep

tics

for

cor

d ca

re10

9ch

lorh

exid

ine

digl

ucon

ate

(7 .1

%)

for

cord

car

eso

lutio

n, g

eleq

uiva

lent

to

4% c

hlor

hexi

dine

V

Dis

posa

ble

supp

lies

110

syri

nge

(aut

odis

able

)st

erile

pac

ks1c

c an

d 5c

c

111

IV s

ets

(DR

AP

appr

oved

)st

erile

pac

ks

112

IV c

anul

a (D

RA

P ap

prov

ed)

ster

ile p

acks

16G

, 20G

, 24G

113

adhe

sive

tap

e (h

ypoa

llerg

enic

)ro

ll1

inch

, 2 in

ch

114

surg

ical

gau

ze32

pix

, 40

M

115

cott

on b

anda

gero

ll6 .

5cm

x 2

m

116

abso

rben

t co

tton

woo

lpa

ck50

0gm

117

exam

inat

ion

glov

espa

irs

box

of 1

00 (

smal

l, m

ediu

m, a

nd

larg

e) [

1:2:

1]

118

ster

ile s

urgi

cal g

love

spa

irs

7, 7

½

119

silk

sut

ures

ster

ile p

acks

0, 1

/0, 2

/0, 3

/0, 4

/0

120

face

mas

ks d

ispo

sabl

e

121

bloo

d la

ncet

sst

erile

pac

ks

122

slid

es

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

123

clea

n de

liver

y ki

tsst

erile

pac

ks

• 1

bath

soa

p, 5

0 gr

am w

rapp

ed

• 1

apro

n

• 2

pape

r to

wel

• 2

pair

s of

late

x ex

amin

atio

n gl

oves

(M

)

• 1

plas

tic u

nder

shee

t (a

bout

one

sq

uare

met

er)

• 1

unde

rpad

60

cm x

90

cm

• 2

alco

hol p

ads

• 2

pack

s of

spo

nges

(4

spon

ges)

• 1

ster

ile b

ulb

suck

er

• 2

ster

ile u

mbi

lical

cor

d cl

amp

• 1

ster

ile s

urgi

cal b

lade

• 2

cott

on t

hrea

d (c

ord

ties)

• 1

mat

erni

ty p

ad

• 1

whi

te p

oly

bag

for

disp

osal

• 1

unbl

each

ed d

igni

ty d

rape

• 1

inst

ruct

ion

shee

t


EML FOR BHUs

BH

Us

EMERGENCY TRAY FOR BHU

Sr# Name of Item Strength Quantity

1 injection tranexamic acid 250mg/5ml 10

2 injection atropine 1mg/1ml 10

3 injection adrenaline 0 .1mg/ml 10

4 injection diazepam 5mg/ml 10

5 injection diclofenac sodium 25mg/ml 10

6 injection pheniramine (maleate) 22 .7mg/2ml 10

7 injection hydrocortisone sodium 100mg 1

8 injection lidocaine 2% w/v 5

9 water for injection 5ml 5

10 injection ringer lactate 1,000ml 10

11 injection normal saline 1,000ml 10

12 glyceryl trinitrate sublingual 500mcg 50

13 isosorbide dinitrate sublingual 5mg 10

14 lidocaine gel 1

15 cotton roll BPC 500gms 1

16 compression bandage BPC 5

17 D/S 5 cc 30

18 IV set 20

19 IV cannula 18G, 20G, 22G, 24G 20 (1:2:2:1)

20 silk sutures sterile packs 0, 1/0, 2/0 10

21 ETT (3mm, 3 .5mm, 4mm, 7 .5mm, 8mm) 10

22 Foley catheter All sizes (10 F to 28 F) 12

23 NG tube (14–18 Fr, infant/child: 10–14 Fr) 10


EML FOR RHCs





EML FOR RHCs

RH

Cs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

A

Ane

sthe

tics

loca

l

1

lidoc

aine

(hy

droc

hlor

ide)ª

vial

/am

poul

e5%

(hy

droc

hlor

ide)

in 2

ml a

mpo

ule

to b

e m

ixed

with

7 .5

% g

luco

se

solu

tion

topi

cal f

orm

s2%

gel

, 4%

sol

utio

n

2lig

noca

ine

+ e

pine

phri

ne

(adr

enal

ine)

inje

ctio

n2%

+ 1

:200

000

3lig

noca

ine

+ e

pine

phri

ne

(adr

enal

ine)

dent

al c

artr

idge

2% +

1:8

0 00

0

BA

nalg

esic

s op

ioid

4m

orph

ine

(sul

phat

e or

hy

droc

hlor

ide)

ampo

ule

10m

g/1m

l

5pe

thid

ine

(hyd

roch

lori

de)

ampu

le50

mg/

ml i

n 2m

l

C

Ana

lges

ics/

NSA

IDs

6ac

etyl

salic

ylic

aci

d (d

ispe

rsib

le)

tabl

et30

0mg

7m

efen

amic

aci

dta

blet

250m

g

susp

ensi

on50

mg/

5ml

8di

clof

enac

(so

dium

)ta

blet

50m

g

ampu

le75

mg

in 3

ml

9ib

upro

fenò

tabl

et20

0mg,

400m

g

syru

p20

0mg/

5ml

10pa

race

tam

ol

tabl

et50

0mg

inje

ctio

n15

0mg/

ml

syru

p12

5mg/

5ml

supp

osito

ry10

0mg

DA

nti-A

llerg

ics

and

med

icin

es u

sed

in

anap

hyla

xis

11ª

chlo

rphe

nira

min

e (h

ydro

gen

mal

eate

)ò

tabl

et4m

g

inje

ctio

n10

mg/

ml

syru

p©2m

g/5m

l


EML FOR RHCsEML FOR RHCs

RH

Cs

RH

Cs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

12de

xam

etha

sone

(d

isod

ium

pho

spha

te)

inje

ctio

n4m

g/m

l

tabl

et0 .

5mg

13ep

inep

hrin

e (a

dren

alin

e)am

pule

1mg

/ml

14hy

droc

ortis

one

(sod

ium

su

ccin

ate)

inje

ctio

n10

0mg,

250m

g

15lo

ratid

ine

tabl

et10

mg

syru

p1m

g/m

l

16pr

edni

solo

neª

tabl

et5m

g

E

Ant

idot

es a

nd o

ther

su

bsta

nces

use

d in

po

ison

ings

17at

ropi

ne (

sulfa

te)ò

ampu

le1m

g in

1m

l

18ch

arco

al a

ctiv

ated

pow

der

19di

azep

amin

ject

ion

10m

g

20m

ethy

lthio

nini

um c

hlor

ide

(met

hyle

ne b

lue)

ampu

le10

mg/

ml i

n 10

ml

21na

loxo

ne (

hydr

ochl

orid

e)am

pule

400m

cg in

1m

l

FA

nti-E

pile

ptic

s22

carb

amaz

epin

e ta

blet

200m

g

syru

p10

0mg/

5ml

Fo

r ec

lam

psia

onl

y23

mag

nesi

um s

ulph

ate

inje

ctio

n50

0mg/

ml

24ph

enob

arbi

tal (

sodi

um)

tabl

et30

mg

inje

ctio

n20

0mg/

ml

25ph

enyt

oin

(sod

ium

)ta

blet

100m

g

G

Ant

i-Hel

min

thic

26al

bend

azol

e ta

blet

200m

g

syru

p10

0mg/

5ml

27m

eben

dazo

le (

chew

able

)ta

blet

500m

g (w

ith c

autio

n on

ly fo

r ad

ults

)

28py

rant

el (

pam

oate

)ta

blet

250m

g

syru

p25

0mg/

5ml

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

H

Ant

i-Fun

gal

29

clot

rim

azol

e

vagi

nal c

ream

1%

vagi

nal t

able

t10

0mg,

500m

g

topi

cal c

ream

1% w

/w

30ny

stat

in

tabl

et50

0,00

0 IU

drop

s©10

0,00

0 IU

/ml

pess

ary

100,

000

IU

I

Ant

i-Inf

ectiv

es

Ant

ibio

tics/

an

timic

robi

als

31

amox

icill

in (

trih

ydra

te)

caps

ule/

tab

let

250m

g, 50

0mg

(pre

fera

bly

disp

ersi

ble

tabl

et)

syru

p©12

5mg,

250m

g/5m

l

inje

ctio

n25

0mg,

500m

g

32am

pici

llin

(sod

ium

)

caps

ule

250m

g, 50

0mg

syru

p©12

5mg,

250m

g/5m

l

inje

ctio

n50

0mg

and

1g

33az

ithro

myc

inª

caps

ule

250m

g, 50

0mg

susp

ensi

on12

5mg/

5ml i

n 22

.5m

l

34be

nzat

hine

pen

icill

inin

ject

ion©

0 .6m

IU, 1

.2m

IU

Onl

y fo

r ep

idem

ic m

enin

gitis

35ch

lora

mph

enic

ol

caps

ule

250m

g

(pal

mita

te)

syru

p12

5mg/

5ml

(sod

ium

suc

cina

te)

inje

ctio

n1g

m

Onl

y lis

ted

for

singl

e-do

se tr

eatm

ent o

f un

com

plica

ted

ano-

geni

tal

gono

rrhe

a

36ce

fixim

e* (

trih

ydra

te)

caps

ule

400m

g

37ci

profl

oxac

in (h

ydro

chlo

ride

)ªta

blet

250m

g, 50

0mg

38co

trim

oxaz

oleò

tabl

et©

400m

g +

80m

g

(sul

fam

etho

xazo

le +

tr

imet

hopr

im)

syru

p©20

0mg

+ 4

0mg/

5ml

39do

xycy

clin

e (h

ycla

te)ò

caps

ule

100m

g



RH

Cs

RH

Cs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

40ge

ntam

icin

(su

lfate

)ªin

ject

ion

40m

g, 80

mg

41m

etro

nida

zoleª

(b

enzo

ate)

tabl

et20

0mg,

400m

g

syru

p20

0mg/

5ml

infu

sion

5mg/

ml i

n 10

0ml

42ni

trof

uran

toin

ta

blet

100m

g

43pr

ocai

ne b

enzy

lpen

icill

in

inje

ctio

n1

m IU

; 3

m IU

44ph

enox

ymet

hy/p

enic

illin

(p

otas

sium

)ta

blet

250m

g, 50

0mg

syru

p12

5mg/

5ml

JA

nti-T

uber

culo

sis

med

icin

es45

etha

mbu

tol

tabl

et40

0mg

oral

liqu

id©

25m

g/m

l

As p

er T

B co

ntro

l pro

gram

gu

idel

ines

46is

onia

zid

tabl

et/s

yrup

©50

mg,

100m

g, 30

0mg

47py

razi

nam

ide

tabl

et50

0mg

48ri

fam

pici

nca

psul

e/sy

rup©

150m

g, 30

0mg,

450m

g, 60

0mg

49st

rept

omyc

inin

ject

ion

1gm

50et

ham

buto

l + is

onia

zid

tabl

et40

0mg

+ 1

50m

g

51is

onia

zid

+ r

ifam

pici

nta

blet

75m

g +

150

mg;

150m

g +

300

mg

52is

onia

zid

+ p

yraz

inam

ide

+

rifa

mpi

cin

tabl

et75

mg

+ 4

00m

g +

150

mg

53ri

fam

pici

n +

ison

iazi

d +

py

razi

nam

ide

+ e

tham

buto

lta

blet

150m

g +

75m

g +

40

0mg

+ 2

75m

g

54et

ham

buto

l + is

onia

zid

+

rifa

mpi

cin

tabl

et27

5mg

+ 7

5mg

+ 1

50m

g

K

Ant

i-Dia

betic

s55

glib

encl

amid

eta

blet

5mg

56m

etfo

rmin

(hy

droc

hlor

ide)

tabl

et50

0mg

57in

sulin

reg

ular

inje

ctio

n10

0 IU

/ml

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

58in

sulin

com

pin

ject

ion

30%

+ 7

0% w

/v

L

Ant

imal

aria

l59

chlo

roqu

ine

(pho

spha

te o

r su

lfate

)ta

blet

150m

g

For V

ivax

60pr

imaq

uine

(di

phos

phat

e)ta

blet

15m

g

For

falci

paru

m61

sulp

hado

xine

+ p

yrim

etha

min

e co

-blis

ter/

com

bine

d th

erap

yta

blet

500m

g +

25m

g

To b

e us

ed in

com

bina

tion

(co-

blist

er)

62

arte

suna

te +

sul

phad

oxin

e an

d py

rim

etha

min

eta

blet

co-b

liste

r of

(6+

2) t

able

t, 2

larg

e ta

blet

s–ea

ch h

as s

ulfa

doxi

ne 5

00m

g U

.S .P .

+ p

yrim

etha

min

e 25

mg

U .S

.P—

6 sm

all t

able

ts, e

ach

has

arte

suna

te 5

0mg

U .S

.P .

Man

agem

ent o

f sev

ere

mal

aria

arte

suna

te +

sul

phad

oxin

e an

d py

rim

etha

min

eta

blet

co-b

liste

r of

(6

+ 3

) ta

blet

—3

larg

e ta

blet

, eac

h ha

s su

lfado

xine

50

0mg

U .S

.P . +

pyr

imet

ham

ine

25m

g U

.S .P .

—6

smal

l tab

let,

each

tab

let

has

arte

suna

te 1

00m

g U

.S .P .

63ar

tem

ethe

rin

ject

ion

40m

g/m

l

M

GIT

med

icin

es64

hyos

cine

(bu

tylb

rom

ide)

inje

ctio

n20

mg/

ml

tabl

et10

mg

65ph

loro

gluc

inol

tabl

etph

loro

gluc

inol

80m

g +

tr

imet

hylp

hlor

oglu

cino

l 80m

g

66m

etoc

lopr

amid

e

(hyd

roch

lori

de)ò

tabl

et10

mg

syru

p5m

g/5m

l

inje

ctio

n5m

g/m

l

67om

epra

zoleª

caps

ule

10m

g, 20

mg,

40m

g

68ra

nitid

ine

inje

ctio

n25

mg/

ml i

n 2m

l

tabl

et15

0mg,

250m

g



RH

Cs

RH

Cs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

69

alum

iniu

m h

ydro

xide

+

mag

nesi

um t

risi

licat

eta

blet

250m

g +

500

mg

Reco

mm

ende

d in

co

mbi

natio

n w

ith z

inc

sulp

hate

20m

g di

sper

sible

ta

blet

for

acut

e di

arrh

ea

70O

RS

(low

osm

olar

ity)

sach

et

dry

mix

ture

(lo

w o

smol

arity

fo

rmul

a) in

sac

het

for

1 lit

er o

f so

lutio

n, e

ach

sach

et c

onta

ins

gluc

ose

anhy

drou

s 13

.5gm

B .P .

, tr

isod

ium

citr

ate

dihy

drat

e 2 .

9gm

B .

P ., p

otas

sium

chl

orid

e1 .5

gm B

.P .,

sodi

um c

hlor

ide

2 .6g

m B

.P .

71bi

saco

dyl

tabl

et5m

g

72gl

ycer

insu

ppos

itory

N

Car

diov

ascu

lar

med

icin

es73

glyc

eryl

tri

nitr

ate

subl

ingu

al50

0mcg

74is

osor

bide

din

itrat

eª

subl

ingu

al5m

g

75am

lodi

pine

(be

syla

te)

tabl

et2 .

5mg,

5mg

For

seve

re p

regn

ancy

in

duce

d hy

pert

ensio

n

(PIH

) onl

y76

met

hyld

opa

tabl

et25

0mg,

500m

g

inje

ctio

n25

0mg

For

seve

re P

IH o

nly

77hy

droc

hlor

othi

azid

eªin

ject

ion

20m

g

tabl

et25

mg,

50m

g

78en

alap

ril (

mal

eate

)ta

blet

5mg,

10m

g

79at

enol

olta

blet

5mg,

10m

g, 25

mg

80

furo

sem

ideª

tabl

et20

mg,

40m

g

inje

ctio

n10

mg

O

Oxy

toci

c m

edic

ines

81er

gom

etri

ne

(hyd

roge

n m

alea

te)ª

inje

ctio

n20

0mcg

in 1

ml

82m

isop

rost

olta

blet

200m

cg

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

83ox

ytoc

inin

ject

ion

10 IU

in 1

ml

P

Res

pira

tory

med

icin

es

84sa

lbut

amol

(su

lfate

)ªta

blet

2mg

and

4mg

inha

ler

100m

cg p

er d

ose

85

amm

oniu

m c

hlor

ide

+

chlo

rofo

rm +

men

thol

+

diph

enhy

dram

ine

+ s

odiu

m

citr

ate

antit

ussi

ve e

xpec

tora

nt13

1 .5m

g/5m

l + 2

2mg/

5ml +

1m

g/5m

l + 1

3 .5m

g/5m

l + 5

5mg/

5ml

86am

inop

hylli

nein

ject

ion

25m

g/m

l

Q

Oph

thal

mic

/EN

T

87bo

rogl

ycer

ine

ear

drop

s

(onl

y fo

r w

ax r

emov

ing)

40 .0

0%

88po

lym

yxin

B s

ulph

ate

+

ligno

cain

eea

r dr

ops

each

ml c

onta

ins

Poly

myx

in

B (S

ulph

ate)

:100

0IU

/m

l,Lig

noca

ine:

50m

g/m

l]; 5

ml p

last

ic

bott

le

89ch

lora

mph

enic

ol

eye

drop

s1%

w/v

, 0 .5

% w

/v

90ci

profl

oxac

inª

(h

ydro

chlo

ride

)ey

e/ea

r dr

ops

0 .3%

w/v

91te

trac

yclin

e (h

ydro

chlo

ride

)ªey

e oi

ntm

ent

1%

92xy

lom

etaz

olin

eò ª

nasa

l dro

ps0 .

05%

R

I/V In

fusi

ons

93pl

asm

a ex

pand

erin

fusi

onde

xtra

n 6%

w/v

, glu

cose

5%

w/v

Plas

ma

subs

titut

es94

gluc

ose/

dext

rose

infu

sion

5%, 1

0,%

ampu

le25

%

95no

rmal

sal

ine

infu

sion

0 .9%

96de

xtro

se +

sal

ine

infu

sion

5% +

0 .9

% w

/v



RH

Cs

RH

Cs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

97R

inge

r la

ctat

eªin

fusi

on

infu

sion

1,00

0ml c

onta

ins

calc

ium

ch

lori

de 0

.2gm

U .S

.P .; p

otas

sium

ch

lori

de 0

.3gm

U .S

.P .; s

odiu

m

chlo

ride

6gm

U .S

.P .; 3

.1gm

sod

ium

la

ctat

e U

.S .P .

, ste

rile

wat

er fo

r in

ject

ion

98po

tass

ium

chl

orid

eso

lutio

n11

.2%

in 2

0ml a

mpo

ule

99so

dium

bic

arbo

nate

inje

ctio

n1 .

4% is

oton

ic

100

wat

er fo

r in

ject

ion

ampu

le5m

l, 10

ml

S

Vita

min

s an

d m

iner

als

101

asco

rbic

aci

dta

blet

50m

g, 10

0mg,

500m

g

102

calc

ium

glu

cona

tein

ject

ion

100m

g/m

l in

10-m

l

103

calc

ium

lact

ate

tabl

et50

0mg,

1gm

104

calc

ium

chl

orid

ein

ject

ion

200m

g/m

l

105

ergo

calc

ifero

l (vi

tam

in D

)ªta

blet

1 .25

mg

(50,

000

IU)

106

ferr

ous

salt

(fum

erat

e)ta

blet

equi

vale

nt t

o 60

mg

iron

syru

peq

uiva

lent

to

25m

g/m

l iro

n

107

folic

aci

d ta

blet

1mg,

5mg

108

ferr

ous

salt

+ fo

lic a

cid

tabl

et (

DR

AP

appr

oved

)ta

blet

, equ

ival

ent

to 6

0mg

iron

+

400m

cg fo

lic a

cid

109

mul

tiple

mic

ronu

trie

nts

sach

et

110

retin

ol (

vita

min

A)

tabl

et/c

apsu

le50

,000

IU; 1

00,0

00 IU

; 200

,000

IU

(as

palm

itate

)

111

zinc

sul

phat

edi

sper

sibl

e ta

blet

20m

g

112

vita

min

Kin

ject

ion

10m

g

113

B co

mpl

exta

blet

114

mul

tivita

min

sta

blet

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

T

Der

mat

olog

ical

s11

5be

nzyl

ben

zoat

eò ª

lotio

n5%

, 25%

116

perm

ethr

incr

eam

, lot

ion

5% w

/w

117

cala

min

eªlo

tion

15%

118

coal

tar

lotio

n5%

119

clob

etas

ol (

prop

iona

te)

crea

m0 .

05%

w/w

120

hydr

ocor

tison

eªcr

eam

1%

121

poly

myx

in B

(su

lpha

te)

+

baci

trac

in z

inc

oint

men

t10

,000

IU/g

+ 5

00 IU

/g

122

silv

er s

ulph

adia

zineò

crea

m1%

U

Con

trac

eptiv

es

123

cond

oms

124

ethy

nyle

stra

diolª

+

nore

this

tero

neª

C

O p

ills

35m

cg +

1m

g

125

levo

norg

estr

elª

PO

pill

s30

mcg

126

levo

norg

estr

el

EC p

ills

750

mcg

(pa

ck o

f 2)

127

copp

er T

/mul

tiloa

dIU

CD

128

DM

PA (

med

roxy

prog

este

rone

ac

etat

e)in

ject

ion

150m

g/1m

l

129

nore

this

tero

ne e

nant

ate

inje

ctio

n20

0mg/

ml i

n 1m

l

130

estr

adio

l cyp

iona

te +

m

edro

xypr

oges

tero

ne a

ceta

tein

ject

ion

5mg

+ 2

5mg

VVa

ccin

es a

nd s

era

131

BCG

vac

cine

WH

O a

ppro

ved/

as p

er n

atio

nal E

PI

prog

ram

131

DPT

vac

cine

132

polio

vac

cine

(O

PV t

riva

lant

)/IP

Vor

al/ i

njec

tion

133

hepa

titis

vac

cine



RH

Cs

RH

Cs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

134

mea

sles

vac

cine

135

teta

nus

toxo

id

136

pent

aval

ant

vacc

ine

137

pneu

moc

occa

l vac

cine

138

anti-

rabi

es v

acci

ne (

PVRV

)si

ngle

-dos

e vi

al

139

anti-

snak

e ve

nom

ser

um

WM

isce

llane

ous

140

tran

exam

ic a

cid

inje

ctio

n25

0mg,

500m

g /5

ml

caps

250m

g, 50

0mg

XA

nxio

lytic

s14

1al

praz

olam

tabl

et0 .

5mg

142

diaz

epam

tabl

et2m

g

Y

Ant

isep

tics/

dis

infe

ctan

ts14

3po

vido

ne-io

dine

solu

tion

10%

w/v

Onl

y ch

lorin

e-ba

sed

com

poun

d in

sta

ble

dry

gran

ular

form

143

halo

gena

ted

natr

ium

ph

osph

ate

pow

der

100g

m

144

chlo

rine

bas

e co

mpo

und

pow

der

(0 .1

% a

vaila

ble

chlo

rine

) fo

r so

lutio

n

145

chlo

rhex

idin

e +

cet

erim

ide

solu

tion

1 .5%

w/v

+ 1

5% w

/v

Ant

isep

tics

for

cord

car

e14

6ch

lorh

exid

ine

digl

ucon

ate

(7 .1

%)

for

cord

car

eso

lutio

n, g

eleq

uiva

lent

to

4% c

hlor

hexi

dine

Z

Dis

posa

ble

supp

lies

147

syri

nge

(aut

odis

able

)st

erile

pac

ks1c

c, 5c

c

148

IV s

ets

(DR

AP

appr

oved

)st

erile

pac

ks

149

scal

p ve

in s

et (

DR

AP

appr

oved

)st

erile

pac

ks

150

volu

met

ric

cham

ber

(IV

bure

tte)

ster

ile p

acks

100m

l siz

e

151

IV c

anul

a (D

RA

P ap

prov

ed)

ster

ile p

acks

18G

, 20G

, 22G

, 24G

152

adhe

sive

tap

e (h

ypoa

llerg

enic

)ro

ll1

inch

, 2 in

ch

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

153

ster

ile g

auze

dre

ssin

g7 .

5 x

7 .5

cm (

10 p

ly)

154

liqui

d pa

raffi

n ga

uze

ster

ile p

acks

155

cott

on b

anda

gero

ll6 .

5cm

x 2

m

156

abso

rben

t co

tton

woo

lpa

ck50

0gm

157

crep

e ba

ndag

e7 .

5, 1

0 cm

x 2

.7m

158

exam

inat

ion

glov

espa

irs

box

of 1

00

(sm

all,

med

ium

, and

larg

e si

ze)

[1:2

:1]

159

ster

ile s

urgi

cal g

love

spa

irs

6, 6

½, 7

, 7½

160

silk

sut

ures

ste

rile

12/p

ack

0, 1

/0, 2

/0, 3

/0, 4

/0

161

chro

mic

cat

gut

ster

ilest

erile

pac

ks0,

1/0

, 2/0

, 3/0

, 4/0

162

face

mas

ks d

ispo

sabl

e

163

bloo

d la

ncet

sst

erile

pac

ks

164

slid

es

165

air

way

set

of 3

adul

t/pe

diat

ric

166

endo

trac

heal

tub

est

erile

pac

ksse

t of

12

167

resu

scita

tor

bag

with

mas

kad

ult/

pedi

atri

c

168

naso

gast

ric

tube

adul

t/pe

diat

ric



RH

Cs

RH

Cs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

169

clea

n de

liver

y ki

tsst

erile

pac

ks

• 1

bath

soa

p, 5

0 gr

am w

rapp

ed

• 1

apro

n

• 2

pap

er t

owel

• 2

pai

rs o

f lat

ex e

xam

inat

ion

glov

es (

M)

• 1

plas

tic u

nder

shee

t (a

bout

one

sq

uare

met

er)

• 1

unde

rpad

60

cm x

90

cm

• 2

alc

ohol

pad

s

• 2

pac

ks o

f spo

nges

(4

spon

ges)

• 1

ster

ile b

ulb

suck

er

• 2

ste

rile

um

bilic

al c

ord

clam

p

• 1

ster

ile s

urgi

cal b

lade

• 2

cot

ton

thre

ad (

cord

tie

s)

• 1

mat

erni

ty p

ad

• 1

whi

te p

oly

bag

for

ispo

sal

• 1

unbl

each

ed d

igni

ty d

rape

• 1

inst

ruct

ion

shee

t

EMERGENCY TRAY FOR RHC


1 injection dobutamine 50mg/ml 5

2 injection tranexamic acid 250mg/5ml 10

3 injection furosemide 10mg/ml 10

4 injection calcium gluconate 100mg/ml in 10ml 10

5 injection dimenhydrinate 50mg/ml 10

6 injection sodium bicarbonate 8 .4% w/v, 25ml 10

7 injection potassium chloride 11 .2% in 20ml ampoule 5

8 injection atropine 1mg/1ml 10

9 injection adrenaline 0 .1mg/ml 10

10 injection diazepam 5mg/ml 10

11 injection diclofenac sodium 25mg/ml 10

12 injection plasma expander 500ml 5

13 injection hydrocortisone sodium 100mg and 250mg 20 (1:1)

14 injection ranitidine 25mg/ml 10

15 injection aminophylline 25mg/ml 10

16 injection lidocaine 2% w/v, 10ml 10

17 water for injection 5ml 5

18 injection 25% DW 25ml ampoule 10

19 Ringer’s lactate infusion 1000ml 10

20 dextrose infusion 10%, 500ml 10

21 normal saline infusion 1,000ml 10

22normal saline with dextrose

infusion5%, 1,000ml 10

23 lidocaine gel 5

24 cotton roll BPC 500gms 5

25 cotton bandage BPC 4 inch, 6 inch 24

26 D/S (AD) 5 cc 10

27 D/S 10cc 5

28 D/S 1cc 5

29 D/S 20cc 1


EML FOR RHCs

RH

Cs

EMERGENCY TRAY FOR RHC


30 volumetric chamber (IV burette) 5

31 IV set 45

32 IV cannula 16G, 18G, 20G, 22G, 24G 25 (1:1:2:2:1)

33 ETT (3mm, 3 .5mm, 4mm, 7 .5mm, 8mm) 10

34 Foley catheter all sizes (10 F to 28 F) 10


EML FOR THQs





EML FOR THQs

TH

Qs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

A

Ane

sthe

tics

gene

ral

1ha

loth

ane/

isofl

uran

ein

hala

tion

2ni

trou

s ox

ide

inha

latio

n

3ox

ygen

(m

edic

inal

gas

) cy

linde

rin

hala

tion

4ke

tam

ine

(hyd

roch

lori

de)

inje

ctio

n50

mg

/ml i

n 10

ml

5

thio

pent

al s

odiu

min

ject

ion

10m

g/m

l, 20

mg/

ml

B

Mus

cle

rela

xant

s6

neos

tigm

ine

(met

ilsul

fate

)in

ject

ion

2 .5m

g in

1m

l

(bro

mid

e)ta

blet

15m

g

7

suxa

met

honi

um (

chlo

ride

)am

poul

e50

mg/

ml i

n 2m

l

C

Ane

sthe

tics

loca

l8

bupi

vaca

ine

(hyd

roch

lori

de)ª

vial

0 .25

%; 0

.5%

inje

ctio

n fo

r sp

inal

ane

sthe

sia

ampo

ule

(5m

g/m

l) 0 .

5% in

4m

l

9lid

ocai

ne (

hydr

ochl

orid

e)ª

vial

5% (

hydr

ochl

orid

e) in

2ml a

mpo

ule

to b

e m

ixed

with

7 .5

%

gluc

ose

solu

tion

topi

cal f

orm

s2%

gel

, 4%

sol

utio

n

10lig

noca

ine

+ e

pine

phri

ne

(adr

enal

ine)

inje

ctio

n2%

+ 1

:200

,000

11lig

noca

ine

+ e

pine

phri

ne

(adr

enal

ine)

dent

al c

artr

idge

2% +

1:8

0,00

0

Com

plem

enta

ry li

st

12ep

hedr

ine

(hyd

roch

lori

de)

ampo

ule .

30m

g in

1m

l

D

Ana

lges

ics

O

pioi

d/ce

ntra

l act

ing

13m

orph

ine

(sul

phat

e or

hy

droc

hlor

ide)

ampo

ule

10m

g in

1m

l

14pe

thid

ine

(hyd

roch

lori

de)

ampu

le50

mg/

ml i

n 2m

l

15na

lbup

hine

(H

Cl)

inje

ctio

n10

mg/

ml,

20m

g/m

l

16pe

ntaz

ocin

inje

ctio

n30

mg/

ml

EA

nalg

esic

s/N

SAID

s17

acet

ylsa

licyl

ic a

cid

(dis

pers

ible

)di

sper

sibl

e ta

blet

300m

g


EML FOR THQsEML FOR THQs

TH

Qs

TH

Qs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

18di

clof

enac

(so

dium

)

tabl

et50

mg

ampu

le75

mg

in 3

ml

gel

3% w

/w

19ib

upro

fenò

tabl

et20

0, 4

00m

g

gel

10%

w/w

syru

p20

0mg/

5ml

20na

prox

enta

blet

250m

g, 50

0mg

21pa

race

tam

ol

tabl

et50

0mg

syru

p12

5mg/

5ml

inje

ctio

n15

0mg/

ml

supp

osito

ry10

0mg

FM

edic

ines

to

trea

t go

ut22

allo

puri

nol

tabl

et10

0mg

and

300m

g

G

Ant

i-Alle

rgic

s an

d m

edic

ines

use

d in

an

aphy

laxi

s23

chlo

rphe

nira

min

e (h

ydro

gen

mal

eate

)ò ª

tabl

et4m

g

inje

ctio

n10

mg/

ml

syru

p©2m

g/5m

l

24lo

rata

dine

tabl

et10

mg

syru

p1m

g/m

l

25ce

tiriz

ine

tabl

et10

mg

syru

p5m

g/5m

l

26pr

omet

hazi

ne (

HC

l)

tabl

et25

mg

syru

p25

mg/

5ml

inje

ctio

n25

mg/

ml i

n 2m

l

27

dexa

met

haso

ne (

diso

dium

ph

osph

ate)

inje

ctio

n4m

g/m

l

tabl

et0 .

5mg

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

28

epin

ephr

ine

(adr

enal

ine)

ampu

le1m

g /m

l

29

hydr

ocor

tison

e (s

odiu

m

succ

inat

e)in

ject

ion

100m

g, 25

0mg

30pr

edni

solo

neª

tabl

et5m

g

H

Ant

idot

es a

nd o

ther

su

bsta

nces

use

d in

po

ison

ings

31at

ropi

ne (

sulfa

te)ò

ampu

le1m

g in

1m

l

32ch

arco

al a

ctiv

ated

pow

der

33m

ethy

lthio

nini

um c

hlor

ide

(met

hyle

ne b

lue)

ampu

le10

mg/

ml i

n 10

ml

34na

loxo

ne (

hydr

ochl

orid

e)am

pule

400

mcg

in 1

ml

I A

nti-E

pile

ptic

s A

nti-C

onvu

lsiv

es

For

ecle

mps

ia o

nly

35ca

rbam

azep

ine

tabl

et20

0mg

syru

p10

0mg/

5ml

36m

agne

sium

sul

phat

ein

ject

ion

500m

g/m

l

37ph

enob

arbi

tal (

sodi

um)

tabl

et30

mg

inje

ctio

n20

0mg

/ml

38ph

enyt

oin

(sod

ium

)ta

blet

100m

g

syru

p30

mg/

5ml

J A

ntib

iotic

s/

antim

icro

bial

s39

amox

icill

in (

trih

ydra

te)

(pre

fera

bly

disp

ersi

ble

tabl

et)

caps

ule/

tab

let

250m

g, 50

0mg

pow

der

for

susp

ensi

on©

125m

g, 25

0mg/

5ml

inje

ctio

n25

0mg,

500m

g

40am

pici

llin

(sod

ium

)

caps

ule

250m

g, 50

0mg

pow

der

for

susp

ensi

on©

125m

g, 25

0mg/

5ml

inje

ctio

n50

0mg,

1 g

41am

oxic

illin

+ c

lavu

lani

c ac

idta

blet

125m

g am

oxic

illin

+ 3

1 .25

mg

clav

ulan

ic a

cid/

5ml a

nd 2

50m

g am

oxic

illin

+ 6

2 .5m

g cl

avul

anic

ac

id/5

ml



TH

Qs

TH

Qs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

in

ject

ion

1gm

42be

nzat

hine

pen

icill

inin

ject

ion©

0 .6m

IU, 1

.2m

IU

43cl

oxac

illin

caps

ule

250m

g, 50

0mg

pow

der

for

susp

ensi

on©

125m

g, 25

0mg/

5ml

Onl

y lis

ted

for

singl

e-do

se tr

eatm

ent o

f un

com

plica

ted

ano-

geni

tal

gono

rrhe

a

44ce

fixim

e* (

trih

ydra

te)

caps

ule

400m

g

syru

p10

0mg,

200m

g/5m

l

45ce

ftri

axon

e (s

odiu

m)ò

pow

der

for

inje

ctio

n25

0mg,

500m

g, 1g

m

Onl

y fo

r ep

idem

ic m

enin

gitis

46

chlo

ram

phen

icol

ca

psul

e25

0mg

(pal

mita

te)

syru

p12

5mg/

5ml

(sod

ium

suc

cina

te)

inje

ctio

n1g

m

47ci

profl

oxac

in (h

ydro

chlo

ride

)ªta

blet

250m

g, 50

0mg

48az

ithro

myc

inª

caps

ule

250m

g, 50

0mg

susp

ensi

on12

5mg/

5ml i

n 22

.5m

l

Reco

mm

ende

d in

co

mbi

natio

n re

gim

ens

for

erad

icatin

g H

. pylo

ri in

ad

ult.

49cl

arith

rom

ycin

*ta

blet

500m

g

50cl

inda

myc

in (

hydr

ochl

orid

e)ca

psul

e15

0mg,

300m

g

(pho

spha

te)

inje

ctio

n15

0mg/

ml

51co

trim

oxaz

oleò

tabl

et©

400m

g +

80m

g

(sul

fam

etho

xazo

le +

tr

imet

hopr

im)

syru

p©20

0mg

+ 4

0mg/

5ml

52do

xycy

clin

e (h

ycla

te)ò

caps

ule©

100m

g

syru

p©25

mg/

5ml

53ge

ntam

icin

(su

lfate

)ªin

ject

ion

40m

g, 80

mg

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

54

levo

floxa

cin

tabl

et25

0g, 5

00m

g

55m

etro

nida

zoleª

(b

enzo

ate)

tabl

et20

0mg,

400m

g

inje

ctio

n50

0mg

in 1

00-m

l

syru

p20

0mg/

5ml

56ni

trof

uran

toin

ta

blet

100m

g

57pr

ocai

ne b

enzy

lpen

icill

in

inje

ctio

n1m

IU, 3

m IU

58ph

enox

ymet

hylp

enic

illin

(p

otas

sium

)ta

blet

250m

g, 50

0mg

syru

p12

5mg/

5ml

KA

nti-H

elm

inth

ic59

albe

ndaz

ole

tabl

et20

0mg

syru

p10

0mg/

5ml

60m

eben

dazo

le (

chew

able

)ta

blet

500m

g (w

ith c

autio

n on

ly fo

r ad

ults

)

61py

rant

el (

pam

oate

)ta

blet

250m

g

syru

p25

0mg/

5ml

L

Ant

i-Fun

gal

62cl

otri

maz

ole

vagi

nal c

ream

1%

vagi

nal t

able

t10

0mg,

500m

g

63flu

cona

zoleª

caps

ule

50m

g

inje

ctio

n2m

g/m

l

syru

p50

mg/

5ml

64ny

stat

inta

blet

500,

000

IU

drop

s©10

0,00

0 IU

/ml

M

Ant

i-Tub

ercu

losi

s m

edic

ines

As p

er T

B Co

ntro

l pro

gram

gu

idel

ines

65et

ham

buto

lta

blet

400m

g

oral

liqu

id©

25m

g/m

l

66is

onia

zid

tabl

et/s

yrup

©50

mg,

100m

g, 30

0mg



TH

Qs

TH

Qs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

67py

razi

nam

ide

tabl

et50

0mg

68ri

fam

pici

nca

ps/s

yrup

©15

0mg,

300m

g, 45

0mg,

600m

g

69st

rept

omyc

inin

ject

ion

1gm

70et

ham

buto

l + is

onia

zid

tabl

et40

0mg

+ 1

50m

g

71is

onia

zid

+ r

ifam

pici

nta

blet

75m

g +

150

mg;

150m

g +

300

mg

72is

onia

zid

+ p

yraz

inam

ide

+

rifa

mpi

cin

tabl

et75

mg

+ 4

00m

g +

150

mg

73ri

fam

pici

n +

ison

iazi

d +

py

razi

nam

ide

+ e

tham

buto

lta

blet

150m

g +

75m

g+

400m

g +

275

mg

74et

ham

buto

l + is

onia

zid

+

rifa

mpi

cin

tabl

et27

5mg

+ 7

5mg

+ 1

50m

g

N

Ant

i-Dia

betic

s75

glib

encl

amid

eta

blet

5mg

76gl

imep

irid

e ta

blet

1mg,

2mg,

3mg

77m

etfo

rmin

(hy

droc

hlor

ide)

tabl

et50

0mg

78in

sulin

reg

ular

inje

ctio

n10

0 IU

/ml

79in

sulin

com

pin

ject

ion

30%

+ 7

0% w

/v

O

Ant

imal

aria

l80

chlo

roqu

ine

(pho

spha

te o

r su

lfate

)ta

blet

150m

g

For

vivax

81pr

imaq

uine

(di

phos

phat

e)ta

blet

15m

g

For

falci

paru

m82

sulp

hado

xine

+ p

yrim

etha

min

eta

blet

500m

g +

25m

g

To b

e us

ed in

com

bina

tion

(co-

blist

er)

83ar

tesu

nate

tabl

et50

mg

Man

agem

ent o

f sev

ere

mal

aria

84ar

tesu

nate

+ s

ulph

adox

ine

+

pyri

met

ham

ine

tabl

et

co-b

liste

r of

(6

+ 2

) ta

blet

—2

larg

e ta

blet

, eac

h ha

s su

lfado

xine

50

0mg

U .S

.P . +

pyr

imet

ham

ine

25m

g U

.S .P

]—6

smal

l tab

lets

, eac

h ha

s ar

tesu

nate

50m

g U

.S .P .

]

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

arte

suna

te +

sul

phad

oxin

e +

py

rim

etha

min

eta

blet

s

co-b

liste

r of

(6

+ 3

) ta

blet

—3

larg

e ta

blet

s, ea

ch h

as s

ulfa

doxi

ne

500m

g U

.S .P .

+ p

yrim

etha

min

e 25

mg

U .S

.P .—

6 sm

all t

able

ts, e

ach

tabl

et

cont

ains

art

esun

ate

100m

g U

.S .P .

85ar

tem

ethe

r*am

pule

80m

g/m

l in

1ml

86ar

tem

ethe

r +

lum

efan

trin

e*ta

blet

©20

mg

+ 1

20m

g

PG

IT m

edic

ines

85hy

osci

ne (

buty

lbro

mid

e)in

ject

ion

20m

g/m

l

tabl

et10

mg

86ph

loro

gluc

inol

tabl

etph

loro

gluc

inol

80m

g +

tr

imet

hylp

hlor

oglu

cino

l 80m

g

87m

etoc

lopr

amid

e

(hyd

roch

lori

de)ò

tabl

et10

mg

syru

p5m

g/5m

l

inje

ctio

n5m

g/m

l

88di

men

hydr

inat

eta

blet

50m

g

89om

epra

zoleª

caps

ule

10m

g, 20

mg,

40m

g

90ra

nitid

ine

inje

ctio

n25

mg/

ml i

n 2m

l

tabl

et15

0mg,

250m

g

91al

umin

ium

hyd

roxi

de +

m

agne

sium

tri

silic

ate

tabl

et25

0mg

+ 5

00m

g

For

trea

tmen

t of a

cute

di

arrh

ea—

in c

ombi

natio

n w

ith z

inc

sulp

hate

20m

g di

sper

sible

tabl

et

92O

RS

(low

osm

olar

ity)

sach

et

dry

mix

ture

(lo

w o

smol

arity

fo

rmul

a) in

sac

het

for

1 lit

er o

f so

lutio

n—ea

ch s

ache

t co

ntai

ns

gluc

ose

anhy

drou

s 13

.5gm

B .P .

, tr

isod

ium

citr

ate

dihy

drat

e 2 .

9gm

B .

P, po

tass

ium

chl

orid

e 1 .

5gm

B .P .

, so

dium

chl

orid

e 2 .

6gm

B .P .

93so

dium

pho

spha

te

enem

a7 .

2g /1

20m

l



TH

Qs

TH

Qs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

94

bisa

cody

lta

blet

5mg

95

glyc

erin

supp

osito

ry

96m

agne

sium

oxi

des

and

hydr

oxid

essu

spen

sion

7 .9%

w/v

QC

ardi

ovas

cula

r m

edic

ines

97ac

etyl

salic

ylic

aci

dta

blet

100m

g

98bi

sopr

ololª

tabl

et1 .

25m

g; 5m

g

99di

goxi

nta

blet

62 .5

mcg

, 250

mcg

inje

ctio

n25

0mcg

/ml i

n 2m

l

100

dopa

min

e (h

ydro

chlo

ride

)in

ject

ion

40m

g/m

l in

5ml v

ial

101

enal

apri

l (m

alea

te)ª

tabl

et2 .

5mg,

5mg

102

glyc

eryl

tri

nitr

ate

subl

ingu

al50

0 m

cg

For

seve

re P

IH o

nly

103

hydr

alaz

ine

(hyd

roch

lori

de)

inje

ctio

n20

mg

tabl

et25

mg,

50m

g

104

isos

orbi

de d

initr

ateª

su

blin

gual

5mg

For

seve

re P

IH o

nly

105

met

hyld

opa

tabl

et25

0mg,

500m

g

inje

ctio

n25

0mg

106

prop

rano

lol (

HC

l)ta

blet

/cap

s10

mg,

40m

g, 80

mg

107

sim

vast

atinª

tabl

et5m

g, 10

mg,

20m

g, 40

mg

108

vera

pam

il (h

ydro

chlo

ride

)ta

blet

40m

g, 80

mg

R

Diu

retic

s

109

furo

sem

ideª

tabl

et20

mg,

40m

g

inje

ctio

n10

mg

110

hydr

ochl

orot

hiaz

ideª

tabl

et12

.5m

g, 25

mg

111

spir

onol

acto

neta

blet

25m

g

SM

edic

ines

affe

ctin

g co

agul

atio

n11

2he

pari

n so

dium

inje

ctio

n1,

000,

5,0

00, 2

0,00

0 IU

/ml

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

11

3tr

anex

amic

aci

din

ject

ion

100m

g/m

l in

10m

l

caps

ule

250m

g, 50

0mg

114

war

fari

n (s

odiu

m)ª

tabl

et1m

g, 2m

g, 5m

g

TA

ntiv

iral

s fo

r he

patit

is

115

inte

rfer

on a

lpha

2b

inje

ctio

n3

MIU

116

riba

viri

neta

blet

200m

g, 40

0mg,

600m

g

UA

nti-H

erpe

s m

edic

ines

117

acyc

lovi

rª

tabl

et20

0mg

syru

p20

0mg/

5ml

crea

m/o

intm

ent

5% w

/w

VO

xyto

cic

med

icin

es11

8er

gom

etri

ne

(hyd

roge

n m

alea

te)ª

inje

ctio

n20

0mcg

in 1

ml

119

mis

opro

stol

tabl

et20

0mcg

120

oxyt

ocin

inje

ctio

n10

IU in

1m

l

W

Res

pira

tory

med

icin

es

121

amin

ophy

lline

in

ject

ion

25m

g/m

l in

10m

l

tabl

et10

0mg

122

becl

omet

haso

ne

(dip

ropi

onat

e)In

hala

tion

(aer

osol

)50

mcg

per

dos

e

123

salb

utam

ol (

sulfa

te)ª

tabl

et2m

g, 4m

g

Inha

latio

n (a

eros

ol)

100m

cg p

er d

ose

solu

tion

for

nebu

lizer

5mg

/ml

inje

ctio

n50

mcg

in 5

ml

124

amm

oniu

m c

hlor

ide

+

chlo

rofo

rm +

men

thol

+

diph

enhy

dram

ine

+ s

odiu

m

citr

ate

antit

ussi

ve e

xpec

tora

nt13

1 .5m

g/5m

l + 2

2mg/

5ml +

1m

g/5m

l + 1

3 .5m

g/5m

l + 5

5mg/

5ml

125

dext

rom

etho

rpha

n +

di

phen

hydr

amin

ean

titus

sive

syr

up12

.5m

g/5m

l + 1

2 .5m

g/5m

l



TH

Qs

TH

Qs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

XO

phth

alm

ic

126

dexa

met

haso

neey

e dr

ops

0 .1%

w/v

127

gent

amic

in (

sulfa

te)ª

eye

drop

s0 .

30%

128

trop

icam

ide

eye

drop

s1%

w/v

129

pilo

carp

ine

(h

ydro

chlo

ride

or

nitr

ate)

eye

drop

s2%

; 4%

130

tetr

acyc

line

(hyd

roch

lori

de)ª

eye

oint

men

t1%

eye

drop

s0 .

50%

131

poly

myx

in B

(su

lpha

te)

+

baci

trac

in z

inc

eye

oint

men

t10

,000

IU/g

+ 5

00 IU

/g

132

tetr

acai

ne (

hydr

ochl

orid

e)

ò ª

drop

s0 .

50%

133

timol

ol (

hydr

ogen

mal

eate

)ªey

e dr

ops

0 .25

%; 0

.5%

YEN

T

134

boro

glyc

erin

eea

r dr

ops

(onl

y fo

r w

ax

rem

ovin

g)40

%

135

poly

myx

in B

sul

phat

e +

lig

noca

ine

ear

drop

s

each

ml c

onta

ins

poly

myx

in

B (s

ulph

ate)

:100

0IU

/m

l,lig

noca

ine:

50m

g/m

l]; 5

ml p

last

ic

bott

le

136

cipr

oflox

acin

ear

drop

s0 .

30%

137

ephe

drin

e na

sal d

rops

0 .5%

138

ligno

cain

eto

pica

l sol

utio

n4%

139

salin

e na

sal d

rops

nasa

l dro

ps0 .

9%

140

xylo

met

azol

ineò

ªna

sal s

pray

0 .05

%

ZA

nti-L

eish

man

iasi

s

med

icin

es14

1am

phot

eric

in B

inje

ctio

n50

mg

in v

ial

142

sodi

um s

tibog

luco

nate

inje

ctio

n10

0mg/

ml i

n 30

ml v

ial

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

AA

I/V

infu

sion

s Pl

asm

a su

bstit

utes

143

plas

ma

expa

nder

infu

sion

dext

ran

6% w

/v,

gluc

ose

5% w

/v

144

gluc

ose/

dext

rose

infu

sion

5, 1

0%

ampu

le25

%

145

norm

al s

alin

ein

fusi

on0 .

9%

146

dext

rose

+ s

alin

ein

fusi

on5%

, 10%

147

Rin

ger’s

lact

ateª

infu

sion

infu

sion

,1,0

00m

l con

tain

s ca

lciu

m

chlo

ride

0 .2

gm U

.S .P .

; pot

assi

um

chlo

ride

0 .3

gm U

.S .P .

; sod

ium

ch

lori

de 6

gm U

.S .P .

; sod

ium

lact

ate

3 .1g

m U

.S .P .

; ste

rile

wat

er fo

r in

ject

ion

1,00

0ml (

q .s .

);1,0

00m

l co

llaps

ible

pla

stic

bot

tle

147

pota

ssiu

m c

hlor

ide

solu

tion

11 .2

% in

20m

l am

poul

e

148

sodi

um b

icar

bona

tein

ject

ion

1 .4%

isot

onic

149

man

nito

lin

fusi

on10

% a

nd 2

0% w

/v (

500m

l)

150

wat

er fo

r in

ject

ion

ampu

le5m

l, 10

ml

AB

D

erm

atol

ogic

als

151

benz

yl b

enzo

ateò

ª

lotio

n5%

, 25%

152

beta

met

haso

neò

ªcr

eam

/oin

tmen

t0 .

1%

153

cala

min

eªlo

tion

15%

154

coal

tar

lotio

n5%

155

clot

rim

azol

eto

pica

l cre

am1%

w/w

156

hydr

ocor

tison

eªcr

eam

1%

157

perm

ethr

incr

eam

/lotio

n5%

/1%

158

salic

ylic

aci

dso

lutio

n5%



TH

Qs

TH

Qs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

15

9po

lym

yxin

B (

sulp

hate

) +

ba

citr

acin

zin

coi

ntm

ent

10,0

00 IU

/g +

500

IU

/g

160

silv

er s

ulph

adia

zineò

crea

m1%

161

sodi

um t

hios

ulph

ate

solu

tion

15%

AC

Vita

min

s an

d m

iner

als

162

asco

rbic

aci

dta

blet

50m

g, 10

0mg,

500m

g

163

calc

ium

glu

cona

tein

ject

ion

100m

g/m

l in

10m

l

164

calc

ium

lact

ate

tabl

et50

0mg,

1gm

165

ergo

calc

ifero

l (vi

tam

in D

)ªta

blet

1 .25

mg

(50,

000

IU)

166

ferr

ous

salt

(fum

erat

e)ta

blet

equi

vale

nt t

o 60

mg

iron

syru

peq

uiva

lent

to

25m

g/m

l iro

n

167

folic

aci

d ta

blet

0 .5m

g, 1m

g, an

d 5m

g

168

ferr

ous

salt

+ fo

lic a

cid

tabl

et (

DR

AP

appr

oved

)ta

blet

, equ

ival

ent

to 6

0mg

iron

+

400

mcg

folic

aci

d

169

vita

min

Kin

ject

ion

10m

g

170

hydr

oxoc

obal

amin

ampu

le1m

g in

1m

l

171

mul

tiple

mic

ronu

trie

nts

sach

et

172

retin

ol (

vita

min

A)

tabl

et/ c

apsu

le50

,000

IU; 1

00,0

00 IU

; 200

,000

IU

(as

palm

itate

)

For

acut

e di

arrh

ea

173

zinc

sul

phat

edi

sper

sibl

e ta

blet

20m

g

174

B co

mpl

ex (

B1, B

6, a

nd B

12)

tabl

et

175

mul

tivita

min

sta

blet

AD

Con

trac

eptiv

es17

6co

ndom

s

177

ethy

nyle

stra

diolª

+

nore

this

tero

neª

co

mbi

ned

oral

pill

s35

mcg

+ 1

mg

178

levo

norg

estr

elª

pr

oges

tero

n on

ly p

ills

30m

cg

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

17

9le

vono

rges

trel

em

erge

ncy

cont

race

ptiv

e pi

lls75

0 m

cg (

pack

of 2

)

180

copp

er T

/mul

tiloa

dIU

CD

181

DM

PA (

med

roxy

prog

este

rone

ac

etat

e)in

ject

ion

150m

g /1

ml

182

nore

this

tero

ne e

nant

ate

inje

ctio

n20

0mg/

ml i

n 1m

l

183

estr

adio

l cyp

iona

te +

m

edro

xypr

oges

tero

ne a

ceta

tein

ject

ion

5mg

+ 2

5mg

184

levo

norg

estr

el-r

elea

sing

im

plan

tsu

bder

mal

impl

ant

2 ro

d 75

mg

each

(us

e lif

e: 5

yea

rs)

185

eton

oges

trel

-rel

easi

ng im

plan

tsu

bder

mal

impl

ant

1 ro

d 68

mg

each

(us

e lif

e: 3

yea

rs)

AE

Va

ccin

es a

nd s

era

186

BCG

vac

cine

WH

O a

ppro

ved/

as p

er

natio

nal E

PI p

rogr

am

187

DPT

vac

cine

188

polio

vac

cine

(O

PV t

riva

lant

)/IP

Vor

al/ i

njec

tion

189

hepa

titis

vac

cine

190

mea

sles

vac

cine

191

teta

nus

toxo

id

192

pent

aval

ant

vacc

ine

193

pneu

moc

occa

l vac

cine

194

men

ingo

cocc

al v

acci

ne

195

anti-

rabi

es v

acci

ne (

PRV

R)

sing

le d

ose

vial

>2 .

5 IU

196

anti-

snak

e ve

nom

ser

um

197

anti

D im

mun

oglo

bulin

(h

uman

)si

ngle

dos

e vi

al25

0mg

198

diph

ther

ia a

ntito

xin

vial

10,0

00 IU

; 20,

000

IU



TH

Qs

TH

Qs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

199

teta

nus

imm

unog

lobu

lin

(hum

an)

inje

ctio

n50

0 IU

in v

ial

200

rabi

es im

mun

oglo

bulin

(h

uman

)vi

al15

0 IU

/ml

AF

M

edic

ines

for

men

tal a

nd

beha

vior

al d

isor

ders

201

chlo

rpro

maz

ine

(hyd

roch

lori

de)ª

inje

ctio

n25

mg

in 2

ml

tabl

et10

0mg

202

halo

peri

dol

tabl

et5m

g

203

alpr

azol

amta

blet

0 .5m

g

Tran

quili

zers

204

diaz

epam

tabl

et2m

g, 5m

g

inje

ctio

n10

mg

Ant

i-Mig

rain

e 20

5m

igri

lta

blet

206

caaf

ergo

tta

blet

AG

A

ntis

eptic

s/

disi

nfec

tant

s20

7po

vido

ne-io

dine

solu

tion

10%

w/v

Onl

y ch

lorin

e-ba

sed

com

poun

d in

sta

ble

dry

gran

ular

form

250

halo

gena

ted

natr

ium

ph

osph

ate

pow

der

100g

m

208

chlo

rhex

idin

e +

cet

erim

ide

solu

tion

1 .5%

w/v

+ 1

5% w

/v

209

acri

flavi

necr

eam

0 .1%

w/w

210

tinct

ure

benz

oin

Co

Solu

tion

7 .5%

w/v

Antis

eptic

s fo

r co

rd c

are

211

chlo

rhex

idin

e di

gluc

onat

e (7

.1%

) fo

r co

rd c

are

solu

tion,

gel

equi

vale

nt t

o 4%

chl

orhe

xidi

ne

AH

Dis

posa

ble

supp

lies

212

syri

nge

(aut

odis

able

)st

erile

pac

ks1c

c, 5c

c

213

disp

osab

le s

yrin

gest

erile

pac

ks50

cc

214

IV s

ets

(DR

AP

appr

oved

)st

erile

pac

ks

215

scal

p ve

in s

et (

DR

AP

appr

oved

)st

erile

pac

ks

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

216

volu

met

ric

cham

ber

(IV

bure

tte)

ster

ile p

acks

100m

l siz

e

217

IV c

anul

a (D

RA

P ap

prov

ed)

ster

ile p

acks

16G

, 20G

, 24G

218

adhe

sive

tap

e (h

ypoa

llerg

enic

)ro

ll1

inch

, 2 in

ch

219

ster

ile g

auze

dre

ssin

g7 .

5 x

7 .5

cm (

10 p

ly)

220

cott

on b

anda

gero

ll6 .

5cm

x 2

m

221

abso

rben

t co

tton

woo

lpa

ck50

0gm

222

crep

e ba

ndag

ero

ll7 .

5, 1

0cm

x 2

.7m

223

exam

inat

ion

glov

espa

irs

box

of 1

00 (

smal

l, m

ediu

m a

nd la

rge

size

) [1

:2:1

]

224

ster

ile s

urgi

cal g

love

spa

irs

6, 6

½, 7

, 7½

, 8

225

silk

sut

ures

ste

rile

12/p

ack

0, 1

/0, 2

/0, 3

/0, 4

/0

226

chro

mic

cat

gut

ster

ilest

erile

pac

ks0,

1/0

, 2/0

, 3/0

, 4/0

227

silk

sut

ures

ste

rile

12/p

ack

8/0,

10/

0

228

prol

ene/

vicr

yl s

teri

le s

utur

esst

erile

pac

ks0,

1/0

, 2/0

, 3/0

, 4/0

229

plas

ter

of p

aris

ban

dage

roll

10cm

, 20c

m x

6m

230

face

mas

ks d

ispo

sabl

e

231

bloo

d la

ncet

sst

erile

pac

ks

232

slid

esst

erile

pac

ks

233

endo

trac

heal

tub

est

erile

pac

ksse

t of

12

234

naso

gast

ric

tube

ster

ile p

acks

adul

t/pa

ds

235

Fole

y ca

thet

erst

erile

pac

ksal

l siz

es

236

urin

e ba

gsst

erile

pac

ks

237

bloo

d ba

gsst

erile

pac

ks

238

disp

osab

le a

irw

ays

ster

ile p

acks

all s

izes


EML FOR THQs

TH

Qs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

239

suct

ion

cath

eter

ster

ile p

acks

240

disp

osab

le c

ord

clam

psst

erile

pac

ks

241

spin

al n

eedl

est

erile

pac

ks

242

surg

ical

bla

des

ster

ile p

acks

cl

ean

deliv

ery

kits

ster

ile p

acks

• 1

bath

soa

p, 5

0 gr

am w

rapp

ed

• 1

apro

n

• 2

pap

er t

owel

• 2

pai

rs o

f lat

ex e

xam

inat

ion

glov

es (

M)

• 1

plas

tic u

nder

shee

t (a

bout

one

sq

uare

met

er)

• 1

unde

rpad

60

cm x

90

cm

• 2

alc

ohol

pad

s

• 2

pac

ks o

f spo

nges

(4

spon

ges)

• 1

ster

ile b

ulb

suck

er

• 2

ste

rile

um

bilic

al c

ord

clam

p

• 1

ster

ile s

urgi

cal b

lade

• 2

cot

ton

thre

ad (

cord

tie

s)

• 1

mat

erni

ty p

ad

• 1

whi

te p

oly

bag

for

disp

osal

• 1

unbl

each

ed d

igni

ty d

rape

• 1

inst

ruct

ion

shee

t

AI

Rad

ioco

ntra

st m

edia

24

3am

idot

rizo

ate

inje

ctio

n14

0mg

to 4

20m

g

iodi

ne/m

l in

20m

l

244

bari

um s

ulfa

teaq

ueou

s su

spen

sion

245

Iohe

xol

inje

ctio

n14

0mg

to 3

50m

g io

dine

/ml

in 5

ml;

10m

l; 20

ml a

mpo

ules

EML FOR DHQs





EML FOR DHQs

DH

Qs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

A

Ane

sthe

tics

gene

ral

1ha

loth

ane/

isofl

uran

ein

hala

tion

2ni

trou

s ox

ide

inha

latio

n

3ox

ygen

(m

edic

inal

gas

) cy

linde

rin

hala

tion

4ke

tam

ine

(hyd

roch

lori

de)

inje

ctio

n50

mg/

ml i

n 10

ml

5th

iope

ntal

(so

dium

)in

ject

ion

10m

g/m

l, 20

mg/

ml

B

Mus

cle

rela

xant

s6

atra

curi

um (

besy

late

)ªin

ject

ion

10m

g/m

l

7ne

ostig

min

e (m

etils

ulfa

te)

inje

ctio

n2 .

5mg

in 1

ml

(bro

mid

e)ta

blet

15m

g

8su

xam

etho

nium

(ch

lori

de)

ampo

ule

50m

g/m

l in

2ml

C

Ane

sthe

tics

loca

l9

bupi

vaca

ine

(hyd

roch

lori

de)ª

vial

0 .25

%, 0

.5%

inje

ctio

n fo

r sp

inal

ane

sthe

sia

ampo

ule

(5m

g/m

l) 0 .

5% in

4m

l

10lid

ocai

ne (

hydr

ochl

orid

e)ª

vial

5% (

hydr

ochl

orid

e) in

2m

l am

poul

e to

be

mix

ed w

ith 7

.5%

glu

cose

so

lutio

n .

topi

cal f

orm

s2%

gel

, 4%

sol

utio

n

11lig

noca

ine

+ e

pine

phri

ne

(adr

enal

ine)

inje

ctio

n2%

+ 1

:200

,000

12lig

noca

ine

+ e

pine

phri

ne

(adr

enal

ine)

dent

al c

artr

idge

2% +

1:8

0,00

0

13ep

hedr

ine

(hyd

roch

lori

de)

ampo

ule

30m

g in

1m

l

D

Ana

lges

ics

O

pioi

d/ce

ntra

l act

ing

14m

orph

ine

(sul

phat

e or

hy

droc

hlor

ide)

ampo

ule

10m

g/1m

l

15pe

thid

ine

(hyd

roch

lori

de)

ampu

le50

mg/

ml i

n 2m

l

nalb

uphi

ne (

HC

l)in

ject

ion

10m

g/m

l, 20

mg/

ml


EML FOR DHQsEML FOR DHQs

DH

Qs

DH

Qs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

16m

idaz

olam

inje

ctio

n1m

g/m

l

tabl

et7 .

5mg

EA

nalg

esic

s/N

SAID

s17

acet

ylsa

licyl

ic a

cid

disp

ersi

ble

tabl

et30

0mg

supp

osito

ry50

mg

to 1

50m

g

18di

clof

enac

(so

dium

)

tabl

et50

mg

ampu

le75

mg

in 3

ml

gel

3% w

/w

19na

prox

enta

blet

250m

g, 50

0mg

20m

elox

icam

tabl

et7 .

5mg,

15m

g

21ib

upro

fenò

tabl

et20

0mg,

400m

g

gel

10%

w/w

syru

p20

0mg/

5ml

22pa

race

tam

ol

tabl

et50

0mg

syru

p12

5mg/

5ml

inje

ctio

n15

0mg/

ml

supp

osito

ry10

0mg

FM

edic

ines

to

trea

t go

ut23

allo

puri

nol

tabl

et10

0mg

GA

nti-A

llerg

ics

and

med

icin

es u

sed

in

anap

hyla

xis

24ch

lorp

heni

ram

ine

(hyd

roge

n

mal

eate

)ò ª

tabl

et4m

g

inje

ctio

n10

mg/

ml

syru

p©2m

g/5m

l

25ce

tiriz

ine

tabl

et10

mg

syru

p5m

g/5m

l

26lo

rata

dine

tabl

et10

mg

syru

p1m

g/m

l

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

27pr

omet

hazi

ne (

HC

l)

tabl

et25

mg

syru

p25

mg/

5ml

inje

ctio

n25

mg/

ml i

n 2m

l

28de

xam

etha

sone

(d

isod

ium

pho

spha

te)

inje

ctio

n4m

g/m

l

tabl

et0 .

5mg

29ep

inep

hrin

e (a

dren

alin

e)am

pule

1mg

/ml

30hy

droc

ortis

one

(sod

ium

su

ccin

ate)

inje

ctio

n10

0mg,

250m

g

31pr

edni

solo

neª

tabl

et5m

g

H

AN

TI-I

NFE

CT

IVES

A

ntib

iotic

s/ a

ntim

icro

bial

32

amox

icill

in (

trih

ydra

te)

caps

ule/

tab

let

250m

g, 50

0mg

(pre

fera

bly

disp

ersi

ble

tabl

et)

pow

der

for

susp

ensi

on©

125m

g, 25

0mg

/5m

l

inje

ctio

n25

0mg,

500m

g

33am

pici

llin

(sod

ium

)

caps

ule

250m

g, 50

0mg

pow

der

for

susp

ensi

on©

125m

g, 25

0mg/

5ml

inje

ctio

n50

0mg

and

1g

Rese

rved

2nd

line

34

amik

acin

(su

lfate

)in

ject

ion

500m

g, 1g

m

35az

ithro

myc

inª

caps

ule

250m

g, 50

0mg

susp

ensi

on12

5mg/

5ml i

n 22

.5m

l

36am

oxic

illin

+ c

lavu

lani

c ac

idta

blet

375m

g

inje

ctio

n1g

m

37be

nzat

hine

pen

icill

inin

ject

ion©

0 .6m

IU, 1

.2 m

IU

38cl

oxac

illin

caps

ule

250m

g, 50

0mg

pow

der

for

susp

ensi

on©

125m

g, 25

0mg/

5ml



DH

Qs

DH

Qs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

Onl

y lis

ted

for

sing

le-

dose

tre

atm

ent

of

unco

mpl

icat

ed a

no-

geni

tal g

onor

rhea

39ce

fixim

e* (

trih

ydra

te)

caps

ule

400m

g

syru

p10

0mg,

200m

g/5m

l

40ce

ftri

axon

e (s

odiu

m)ò

pow

der

for

inje

ctio

n25

0mg,

500m

g, 1g

m

Onl

y fo

r ep

idem

ic m

enin

gitis

41

chlo

ram

phen

icol

ca

psul

e25

0mg

(pal

mita

te)

syru

p12

5mg/

5ml

(sod

ium

suc

cina

te)

inje

ctio

n1g

m

42ci

profl

oxac

in (h

ydro

chlo

ride

)ªta

blet

250m

g, 50

0mg

infu

sion

500m

g/10

0ml

Reco

mm

ende

d fo

r us

e in

co

mbi

natio

n re

gim

ens

for

erad

icatio

n of

H. p

ylori

in

adul

ts

43cl

arith

rom

ycin

*ta

blet

500m

g

44cl

inda

myc

in (

hydr

ochl

orid

e)

(pho

spha

te)

caps

ule

150m

g, 30

0mg

inje

ctio

n15

0mg/

ml

45co

trim

oxaz

oleò

(s

ulfa

met

hoxa

zole

+

rim

etho

prim

)

tabl

et©

400m

g +

80m

g

syru

p©20

0mg

+ 4

0mg/

5ml

46do

xycy

clin

e (h

ycla

te)ò

caps

ule©

100m

g

syru

p©25

mg/

5ml

47flu

clox

acill

in

[flox

acill

in s

odiu

m]

inje

ctio

n25

0mg,

500m

g

caps

ule

250m

g, 50

0mg

48ge

ntam

icin

(su

lfate

)ªin

ject

ion

40m

g, 80

mg

for

mul

tidru

g-re

sista

nce

(MD

R) tu

berc

ulos

is (T

B)49

kana

myc

in (

sulfa

te)

inje

ctio

n50

0mg,

1gm

50le

voflo

xaci

nta

blet

250m

g, 50

0mg

inje

ctio

n50

0mg

51m

etro

nida

zoleª

ta

blet

200m

g, 40

0mg

inje

ctio

n50

0mg

in 1

00m

l

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

(b

enzo

ate)

syru

p20

0mg/

5ml

52

nitr

ofur

anto

in

tabl

et10

0mg

53pr

ocai

ne b

enzy

lpen

icill

in

inje

ctio

n1m

IU, 3

m IU

54ph

enox

ymet

hylp

enic

illin

(p

otas

sium

)ta

blet

250m

g, 50

0mg

syru

p12

5mg/

5ml

55va

ncom

ycin

(H

Cl)

inje

ctio

n50

0mg

I A

ntid

otes

and

oth

er

subs

tanc

es u

sed

in

pois

onin

gs

56at

ropi

ne (

sulfa

te)ò

ampu

le1m

g in

1m

l

57ch

arco

al a

ctiv

ated

pow

der

58m

ethy

lthio

nini

um c

hlor

ide

(met

hyle

ne b

lue)

ampu

le10

mg/

ml i

n 10

ml

59na

loxo

ne (

hydr

ochl

orid

e)am

pule

400

mcg

in 1

ml

J A

nti-E

pile

ptic

s A

ntic

onvu

lsan

ts

For

ecle

mps

ia o

nly

60ca

rbam

azep

ine

tabl

et20

0mg

syru

p10

0mg/

5ml

61m

agne

sium

sul

phat

ein

ject

ion

500m

g/m

l

62ph

enob

arbi

tal (

sodi

um)

tabl

et30

mg

inje

ctio

n20

0mg

/ml

63va

lpro

ic a

cid

(sod

ium

va

lpro

ate)

inje

ctio

n20

0mg/

5ml

tabl

et20

0mg,

500m

g

64ph

enyt

oin

(sod

ium

)ta

blet

100m

g

syru

p30

mg/

5ml

K

Ant

i-Hel

min

thic

65al

bend

azol

e ta

blet

200m

g

syru

p10

0mg/

5ml

66m

eben

dazo

le (

chew

able

)ta

blet

500m

g (w

ith c

autio

n—on

ly fo

r ad

ults

)

67py

rant

el (

pam

oate

)ta

blet

250m

g

syru

p25

0mg/

5ml



DH

Qs

DH

Qs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

LA

nti-F

unga

l68

clot

rim

azol

eva

gina

l cre

am1%

w/v

vagi

nal t

able

t10

0mg,

500m

g

69flu

cona

zoleª

caps

ule

50m

g

inje

ctio

n2m

g/m

l

syru

p50

mg/

5ml

70ny

stat

in

tabl

et50

0,00

0 IU

drop

s©10

0,00

0 IU

/ml

pess

ary

100,

000

IU

M

Ant

i-Tub

ercu

losi

s dr

ugs

As

per T

B co

ntro

l pr

ogra

m g

uide

lines

71et

ham

buto

lta

blet

400m

g

oral

liqu

id©

25m

g/m

l

72is

onia

zid

tabl

et/s

yrup

©50

mg,

100m

g, 30

0mg

73py

razi

nam

ide

tabl

et50

0mg

74ri

fam

pici

nca

psul

es/s

yrup

©15

0mg,

300m

g, 45

0mg,

600m

g

75st

rept

omyc

inin

ject

ion

1gm

76et

ham

buto

l + is

onia

zid

tabl

et40

0mg

+ 1

50m

g

77is

onia

zid

+ r

ifam

pici

nta

blet

75m

g +

150

mg;

150m

g +

300

mg

78is

onia

zid

+ p

yraz

inam

ide

+

rifa

mpi

cin

tabl

et75

mg

+ 4

00m

g +

150

mg

79ri

fam

pici

n +

ison

iazi

d +

ta

blet

80et

ham

buto

l + is

onia

zid

+

rifa

mpi

cin

tabl

et27

5mg

+ 7

5mg

+ 1

50m

g

NA

nti-H

erpe

s m

edic

ines

81ac

iclo

virª

tabl

et20

0mg

OA

nti-L

eish

man

iasi

s

med

icin

es82

amph

oter

icin

bin

ject

ion

50m

g in

via

l

83so

dium

stib

oglu

cona

tein

ject

ion

100m

g/m

l in

30m

l via

l

PA

nti-D

iabe

tics

84gl

iben

clam

ide

tabl

et5m

g

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

85gl

imep

irid

e ta

blet

1mg,

2mg,

3mg

86m

etfo

rmin

(hy

droc

hlor

ide)

tabl

et50

0mg

87in

sulin

reg

ular

inje

ctio

n10

0 IU

/ml

88in

sulin

com

pin

ject

ion

30%

+ 7

0% w

/v

Q

Ant

imal

aria

l89

chlo

roqu

ine

(pho

spha

te o

r su

lfate

)ta

blet

150m

g

syru

p50

mg/

5ml

90qu

inin

eta

blet

300m

g

inje

ctio

n30

0mg/

ml

For

vivax

91pr

imaq

uine

(di

phos

phat

e)ta

blet

15m

g

For

falci

paru

m92

sulp

hado

xine

+ p

yrim

etha

min

eta

blet

500m

g +

25m

g

To b

e us

ed in

com

bina

tion

(co-

blist

er)

93

arte

suna

te +

sul

phad

oxin

e +

py

rim

etha

min

eta

blet

co-b

liste

r of

(6

+ 2

) ta

blet

—tw

o la

rge

tabl

ets,

each

has

sul

fado

xine

50

0mg

U .S

.P . +

pyr

imet

ham

ine

25m

g U

.S .P

—si

x sm

all t

able

ts ,e

ach

cont

ains

art

esun

ate

50m

g U

.S .P .

arte

suna

te +

sul

phad

oxin

e an

d py

rim

etha

min

eta

blet

co-b

liste

r of

(6

+ 3

) ta

blet

—3

larg

e ta

blet

s, ea

ch h

as s

ulfa

doxi

ne

500m

g U

.S .P .

+ p

yrim

etha

min

e 25

mg

U .S

.P .—

6 sm

all t

able

ts, e

ach

tabl

et

cont

ains

art

esun

ate

100m

g U

.S .P .

Man

agem

ent o

f sev

ere

mal

aria

94

arte

met

her*

ampu

le80

mg/

ml i

n 1m

l

95ar

tem

ethe

r +

lum

efan

trin

e*ta

blet

©20

mg

+ 1

20m

g

R

GIT

med

icin

es96

hyos

cine

(bu

tylb

rom

ide)

inje

ctio

n20

mg/

ml

tabl

et10

mg

97ph

loro

gluc

inol

tabl

etph

loro

gluc

inol

80m

g +

tr

imet

hylp

hlor

oglu

cino

l 80m

g



DH

Qs

DH

Qs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

98

met

oclo

pram

ide

(hyd

roch

lori

de)ò

tabl

ets

10m

g

syru

p5m

g/5m

l

inje

ctio

n5m

g/m

l

99om

epra

zoleª

caps

ules

10m

g, 20

mg,

40m

g

100

rani

tidin

ein

ject

ion

25m

g/m

l in

2ml

tabl

ets

150m

g, 25

0mg

101

alum

iniu

m h

ydro

xide

+

mag

nesi

um t

risi

licat

eta

blet

s25

0mg

+ 5

00m

g

Reco

mm

ende

d in

co

mbi

natio

n w

ith z

inc

sulp

hate

20m

g di

sper

sible

ta

blet

in c

ase

of a

cute

di

arrh

ea10

2O

RS

(low

osm

olar

ity)

sach

et

Dry

mix

ture

(lo

w o

smol

arity

fo

rmul

a) in

sac

het

for

1 lit

er o

f so

lutio

n, e

ach

sach

et c

onta

ins

gluc

ose

anhy

drou

s 13

.5gm

B .P .

, tr

isod

ium

citr

ate

dihy

drat

e 2 .

9gm

B .

P ., p

otas

sium

chl

orid

e1 .5

gm B

.P .,

sodi

um c

hlor

ide

2 .6g

m B

.P .

103

sodi

um p

hosp

hate

en

ema

7 .2g

/120

ml

104

lact

ulos

esy

rup

3 .35

g/5m

l in

120m

l

105

bisa

cody

lta

blet

5mg

106

glyc

erin

supp

osito

ry

107

mag

nesi

um o

xide

and

hy

drox

ide

susp

ensi

on7 .

9% w

/v

S

Ant

ivir

als

for

hepa

titis

108

inte

rfer

on a

lpha

2b

inje

ctio

n3

mill

ion

inte

rnat

iona

l uni

ts (

MIU

)

109

riba

viri

neta

blet

200m

g, 40

0mg,

600m

g

110

lam

ivud

ine

tabl

et15

0mg

T

Car

diov

ascu

lar

med

icin

es11

1ac

etyl

salic

ylic

aci

dta

blet

100m

g

112

biso

prol

olª

tabl

et1 .

25m

g, 5m

g

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

11

3di

goxi

nta

blet

62 .5

mcg

, 250

mcg

inje

ctio

n25

0mcg

/ml i

n 2m

l

114

dopa

min

e (h

ydro

chlo

ride

)in

ject

ion

40m

g/m

l in

5ml v

ial

115

dobu

tam

ine

(hyd

roch

lori

de)

inje

ctio

n50

mg/

ml i

n 5m

l

116

enal

apri

l (m

alea

te)ª

tabl

et2 .

5mg,

5mg

117

glyc

eryl

tri

nitr

ate

subl

ingu

al50

0 m

cg

For

seve

re P

IH o

nly

118

hydr

alaz

ine

(hyd

roch

lori

de)

inje

ctio

n20

mg

tabl

et25

mg,

50m

g

119

isos

orbi

de d

initr

ateª

su

blin

gual

5mg

For

seve

re P

IH o

nly

120

met

hyld

opa

tabl

et25

0mg,

500m

g

inje

ctio

n25

0mg

121

losa

rtan

ta

blet

25m

g, 50

mg,

100m

g

122

prop

rano

lol (

HC

l)ta

blet

/cap

s10

mg,

40m

g, 80

mg

123

stre

ptok

inas

epo

wde

r fo

r in

ject

ion

1 .5

mill

ion

IU

124

sim

vast

atinª

tabl

et5m

g, 10

mg,

20m

g, 40

mg

125

vera

pam

il (h

ydro

chlo

ride

)ta

blet

40m

g, 80

mg

UD

iure

tics

126

furo

sem

ideª

tabl

et20

mg,

40m

g

inje

ctio

n10

mg

127

hydr

ochl

orot

hiaz

ideª

tabl

et12

.5m

g, 25

mg

128

spir

onol

acto

neta

blet

25m

g

V

Med

icin

es a

ffect

ing

co

agul

atio

n12

9he

pari

n (s

odiu

m)

inje

ctio

n1,

000,

5,0

00, 2

0,00

0 IU

/ml

130

tran

exam

ic a

cid

inje

ctio

n10

0mg/

ml i

n 10

ml

caps

ule

250m

g, 50

0mg

131

clop

idog

rel

tabl

et75

mg,

150m

g, 30

0mg

132

war

fari

n (s

odiu

m)ª

tabl

et1m

g, 2m

g, 5m

g



DH

Qs

DH

Qs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

W

Oxy

toci

c m

edic

ines

133

ergo

met

rine

(h

ydro

gen

mal

eate

)ªin

ject

ion

200m

cg in

1m

l

134

mis

opro

stol

tabl

et20

0mcg

135

oxyt

ocin

inje

ctio

n10

IU in

1m

l

X

Res

pira

tory

med

icin

es

136

amin

ophy

lline

in

ject

ion

25m

g/m

l in

10m

l

tabl

et10

0mg

137

becl

omet

haso

ne

(dip

ropi

onat

e)in

hale

r50

mcg

per

dos

e

138

salb

utam

ol (

sulfa

te)ª

tabl

et2m

g, 4m

g

inha

ler

100m

cg p

er d

ose

solu

tion

for

nebu

lizer

5mg

/ml

inje

ctio

n50

mcg

in 5

ml

139

amm

oniu

m c

hlor

ide

+

chlo

rofo

rm +

men

thol

+

diph

enhy

dram

ine

+ s

odiu

m

citr

ate

antit

ussi

ve e

xpec

tora

nt13

1 .5m

g/5m

l + 2

2mg/

5ml +

1m

g/5m

l + 1

3 .5m

g/5m

l + 5

5mg/

5ml

140

dext

rom

etho

rpha

n +

di

phen

hydr

amin

ean

titus

sive

syr

up12

.5m

g/5m

l + 1

2 .5m

g/5m

l

Y

Oph

thal

mic

14

1de

xam

etha

sone

eye

drop

s0 .

1% w

/v

142

gent

amic

in (

sulfa

te)ª

eye

drop

s0 .

30%

143

trop

icam

ide

eye

drop

s1%

w/v

144

pilo

carp

ine

(hyd

roch

lori

de o

r ni

trat

e)ey

e dr

ops

2%, 4

%

145

cipr

oflox

acin

eye

drop

s

146

poly

myx

in B

(su

lpha

te)

+

baci

trac

in z

inc

eye

oint

men

t10

,000

IU/g

+ 5

00IU

/g

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

14

7te

trac

yclin

e (h

ydro

chlo

ride

)ªey

e oi

ntm

ent

1%

eye

drop

s0 .

50%

148

tetr

acai

ne (

hydr

ochl

orid

e)ò

ªdr

ops

0 .50

%

149

timol

ol (

hydr

ogen

mal

eate

)ªey

e dr

ops

0 .25

%, 0

.5%

Z

ENT

150

boro

glyc

erin

eea

r dr

ops

(onl

y fo

r w

ax

rem

ovin

g)40

%

151

poly

myx

in B

sul

phat

e +

lig

noca

ine

ear

drop

s

each

ml c

onta

ins

poly

myx

in

B (s

ulph

ate)

:100

0IU

/m

l,Lig

noca

ine:

50m

g/m

l]; 5

ml p

last

ic

bott

le

152

cipr

oflox

acin

ear

drop

s0 .

30%

153

ephe

drin

e na

sal d

rops

0 .5%

154

ligno

cain

eto

pica

l sol

utio

n4%

155

salin

e na

sal d

rops

nasa

l dro

ps0 .

9%

156

xylo

met

azol

ineò

ªna

sal s

pray

0 .05

%

AA

I/V

Infu

sion

s Pl

asm

a su

bstit

utes

157

plas

ma

expa

nder

infu

sion

dext

ran

6% w

/v, g

luco

se 5

% w

/v

158

gluc

ose/

dext

rose

infu

sion

5%, 1

0%

ampu

le25

%

159

norm

al s

alin

ein

fusi

on0 .

9%

160

dext

rose

+ s

alin

ein

fusi

on5%

+ 0

.9%

w/v

161

Rin

ger’s

lact

ateª

in

fusi

on

infu

sion

1,00

0ml c

onta

ins

calc

ium

ch

lori

de 0

.2gm

U .S

.P .; p

otas

sium

ch

lori

de 0

.3gm

U .S

.P .; s

odiu

m

chlo

ride

6gm

U .S

.P .; 3

.1gm

sod

ium

la

ctat

e U

.S .P .

, ste

rile

wat

er fo

r in

ject

ion

162

pota

ssiu

m c

hlor

ide

solu

tion

11 .2

% in

20m

l am

poul

e



DH

Qs

DH

Qs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

163

sodi

um b

icar

bona

tein

ject

ion

1 .4%

isot

onic

164

man

nito

lin

fusi

on20

% w

/v

165

wat

er fo

r in

ject

ion

ampu

le5m

l, 10

ml

AB

Vita

min

s an

d m

iner

als

166

asco

rbic

aci

dta

blet

50m

g, 10

0mg,

500m

g

167

calc

ium

glu

cona

tein

ject

ion

100m

g/m

l in

10m

l

168

calc

ium

lact

ate

tabl

et50

0mg,

1gm

169

ergo

calc

ifero

l (vi

tam

in D

)ªta

blet

1 .25

mg

(50,

000

IU)

170

ferr

ous

salt

tabl

eteq

uiva

lent

to

60m

g ir

on

syru

peq

uiva

lent

to

25m

g/m

l iro

n

171

folic

aci

d ta

blet

0 .5m

g,1m

g, 5m

g

172

ferr

ous

salt

+ fo

lic a

cid

tabl

etta

blet

, equ

ival

ent

to 6

0mg

iron

+

400m

cg fo

lic a

cid

173

vita

min

Kin

ject

ion

10m

g

174

hydr

oxoc

obal

amin

ampu

le1m

g in

1m

l

175

mul

tiple

mic

ronu

trie

nts

sach

et

176

retin

ol (

vita

min

A)

tabl

et/ c

apsu

le50

,000

IU; 1

00,0

00 IU

; 200

,000

IU

(as

palm

itate

)

Acut

e di

arrh

ea

177

zinc

sul

phat

edi

sper

sibl

e ta

blet

20m

g

178

B co

mpl

ex (

B1, B

6, a

nd B

12)

tabl

et

179

mul

tivita

min

sta

blet

AC

Der

mat

olog

ical

s18

0ª

ben

zyl b

enzo

ate ò

lo

tion

5%, 2

5%

181

ª b

etam

etha

sone

òcr

eam

/oin

tmen

t0 .

1%

182

ª c

alam

ine

lotio

n15

%

183

coal

tar

lotio

n5%

184

ª h

ydro

cort

ison

ecr

eam

1%

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

185

perm

ethr

incr

eam

/lotio

n5%

, 1%

186

salic

ylic

aci

dso

lutio

n5%

187

sele

nium

sul

fide

dete

rgen

t-ba

sed

susp

ensi

on2%

188

poly

myx

in B

(su

lpha

te)

+

baci

trac

in z

inc

oint

men

t10

,000

IU/g

+ 5

00 IU

/g

189

silv

er s

ulph

adia

zineò

crea

m1%

190

sodi

um t

hios

ulph

ate

solu

tion

15%

AD

M

edic

ines

for

men

tal a

nd

beha

vior

al d

isor

ders

Tr

anqu

ilize

rs

191

amitr

ipty

line

(hyd

roch

lori

de)

tabl

et25

mg

192

carb

amaz

epin

eta

blet

100m

g, 20

0mg

193

ª c

hlor

prom

azin

e (h

ydro

chlo

ride

)

inje

ctio

n25

mg

in 2

ml

tabl

et10

0mg

194

clom

ipra

min

e (h

ydro

chlo

ride

)ta

blet

10m

g, 25

mg

195

olan

zapi

neta

blet

5mg,

7mg,

5mg

196

risp

erid

one

tabl

et1m

g, 2m

g, 3m

g

197

fluox

etin

e (h

ydro

chlo

ride

) ò

©ta

blet

20m

g

198

ª fl

uphe

nazi

ne (

deca

noat

e or

en

anta

te)

tabl

et25

mg

199

diaz

epam

tabl

et2m

g, 5m

g

inje

ctio

n10

mg

200

alpr

azol

amta

blet

0 .5m

g

201

brom

azep

amta

blet

3mg

AE

C

ontr

acep

tives

202

cond

oms

203

ethy

nyle

stra

diolª

+

nore

this

tero

neª

CO

pill

s35

mcg

+ 1

mg



DH

Qs

DH

Qs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

204

levo

norg

estr

elª

PO p

ills

30m

cg

20

5le

vono

rges

trel

EC

pill

s75

0mcg

(pa

ck o

f 2)

206

copp

er T

/mul

tiloa

dIU

CD

207

med

roxy

prog

este

rone

ace

tate

(D

MPA

)in

ject

ion

150m

g/1m

l

208

nore

this

tero

ne e

nant

ate

inje

ctio

n20

0mg/

ml i

n 1m

l

209

estr

adio

l cyp

iona

te +

m

edro

xy-

prog

este

rone

ace

tate

m

edro

xypr

oges

tero

ne

acet

atem

edro

xypr

oges

tero

ne

acet

ate

inje

ctio

n5m

g +

25m

g

210

levo

norg

estr

el-r

elea

sing

im

plan

tsu

bder

mal

impl

ant

2 ro

d 75

mg

each

(us

e lif

e: 5

yea

rs)

211

eton

oges

trel

-rel

easi

ng im

plan

tsu

bder

mal

impl

ant

1 ro

d 68

mg

each

(us

e lif

e: 3

yea

rs)

AF

Va

ccin

es a

nd s

era

212

BCG

vac

cine

WH

O-a

ppro

ved/

as p

er

natio

nal E

PI p

rogr

am

213

DPT

vac

cine

214

polio

vac

cine

(O

PV t

riva

lent

)/ IP

Vor

al/ i

njec

tion

215

hepa

titis

vac

cine

216

mea

sles

vac

cine

217

teta

nus

toxo

id

218

pent

aval

ant

vacc

ine

219

pneu

moc

occa

l vac

cine

220

men

ingo

cocc

al v

acci

ne

221

anti-

rabi

es v

acci

ne (

PVRV

)si

ngle

-dos

e vi

al >

2 .5

IU

222

anti-

snak

e ve

nom

ser

um

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

223

anti-

D im

mun

oglo

bulin

(h

uman

)si

ngle

-dos

e vi

al25

0 m

icro

gram

s

224

diph

ther

ia a

ntito

xin

vial

10,0

00 IU

; 20

000

IU

225

teta

nus

imm

unog

lobu

lin

(hum

an)

inje

ctio

n50

0 IU

in v

ial

226

rabi

es im

mun

oglo

bulin

(h

uman

)vi

al15

0 IU

/ml

AG

Peri

tone

al d

ialy

sis

solu

tions

227

intr

aper

itone

al d

ialy

sis

solu

tion

pare

nter

al s

olut

ion

of a

ppro

pria

te c

ompo

sitio

n

AH

Im

mun

osup

pres

sive

s22

8az

athi

opri

ne

(as

sodi

um s

alt)

tabl

et50

mg

inje

ctio

n10

0mg

in v

ial

229

cicl

ospo

rin

caps

ule

25m

g

AI

Ant

i-Par

kins

on’s

230

bipe

ride

nin

ject

ion

5mg

(lact

ate)

in 1

ml

tabl

et2m

g (h

ydro

chlo

ride

)

231

levo

dopa

+ c

arbi

dopa

tabl

et10

0mg

+ 1

0mg;

250m

g +

25m

g

Thy

roid

/ ant

i-thy

roid

232

levo

thyr

oxin

eta

blet

50m

cg, 1

00 m

cg

233

prop

ylth

iour

acil

tabl

et50

mg

AJ

Ant

isep

tics

/dis

infe

ctan

ts23

4po

vido

ne-io

dine

solu

tion

10%

w/v

235

chlo

rhex

idin

e +

cet

erim

ide

solu

tion

1 .5%

w/v

+ 1

5% w

/v

Onl

y ch

lorin

e ba

sed

com

poun

d in

sta

ble

dry

gran

ular

form

236

halo

gena

ted

natr

ium

ph

osph

ate

pow

der

100g

ms

237

tinct

ure

benz

oin

com

poun

dso

lutio

n7 .

5% w

/v

Antis

eptic

s fo

r co

rd c

are

238

chlo

rhex

idin

e di

gluc

onat

e (7

.1%

) fo

r co

rd c

are

solu

tion,

gel

equi

vale

nt t

o 4%

chl

orhe

xidi

ne

AK

D

ispo

sabl

e su

pplie

s23

9sy

ring

e (a

utod

isab

le)

ster

ile p

acks

1cc,

5cc

240

disp

osab

le s

yrin

gest

erile

pac

ks50

cc



DH

Qs

DH

Qs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

241

IV s

ets

(DR

AP

appr

oved

)st

erile

pac

ks

242

scal

p ve

in s

et (

DR

AP

appr

oved

)st

erile

pac

ks

243

volu

met

ric

cham

ber

(IV

bure

tte)

ster

ile p

acks

100m

l

244

IV c

anul

a (D

RA

P ap

prov

ed)

ster

ile p

acks

16G

, 20G

, 24G

245

adhe

sive

tap

e (h

ypoa

llerg

enic

)ro

ll1

inch

, 2 in

ch

246

ster

ile g

auze

dre

ssin

g7 .

5 x

7 .5

cm (

10 p

ly)

247

cott

on b

anda

gero

ll6 .

5 cm

x 2

m

248

abso

rben

t co

tton

woo

lpa

ck50

0gm

249

crep

e ba

ndag

ero

ll7 .

5, 1

0 cm

x 2

.7m

250

exam

inat

ion

glov

espa

irbo

x of

100

(sm

all,

med

ium

, and

la

rge)

[1:

2:1]

251

ster

ile s

urgi

cal g

love

spa

ir6,

6½

, 7, 7

½, 8

251

silk

sut

ures

ste

rile

12/p

ack

0, 1

/0, 2

/0, 3

/0, 4

/0

252

chro

mic

cat

gut

ster

ilest

erile

pac

ks0,

1/0

, 2/0

, 3/0

, 4/0

253

silk

sut

ures

ste

rile

12/p

ack

8/0,

10/

0

254

prol

ene/

vicr

yl s

teri

le s

utur

esst

erile

pac

ks0,

1/0

, 2/0

, 3/0

, 4/0

255

plas

ter

of p

aris

ban

dage

roll

10 c

m, 2

0 cm

x 6

m

256

face

mas

ks d

ispo

sabl

e

257

bloo

d la

ncet

sst

erile

pac

ks

258

slid

esst

erile

pac

ks

259

endo

trac

heal

tub

est

erile

pac

ksSe

t of

12

260

naso

gast

ric

tube

ster

ile p

acks

adul

t/pa

ds

261

Fole

y ca

thet

erst

erile

pac

ksal

l siz

es

262

urin

e ba

gsst

erile

pac

ks

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

263

bloo

d ba

gsst

erile

pac

ks

264

disp

osab

le a

irw

ays

ster

ile p

acks

all s

izes

265

suct

ion

cath

eter

ster

ile p

acks

266

disp

osab

le c

ord

clam

psst

erile

pac

ks

267

spin

al n

eedl

est

erile

pac

ks

268

surg

ical

bla

des

ster

ile p

acks

269

clea

n de

liver

y ki

ts

ster

ile p

acks

• 1

bath

soa

p, 5

0 gr

am w

rapp

ed

• 1

apro

n

• 2

pap

er t

owel

• 2

pai

rs o

f lat

ex e

xam

inat

ion

glov

es (

M)

• 1

plas

tic u

nder

shee

t (a

bout

one

sq

uare

met

er)

• 1

unde

rpad

60

cm x

90

cm

• 2

alc

ohol

pad

s

• 2

pac

ks o

f spo

nges

(4

spon

ges)

• 1

ster

ile b

ulb

suck

er

• 2

ste

rile

um

bilic

al c

ord

clam

p

• 1

ster

ile s

urgi

cal b

lade

• 2

cot

ton

thre

ad (

cord

tie

s)

• 1

mat

erni

ty p

ad

• 1

whi

te p

oly

bag

for

disp

osal

• 1

unbl

each

ed d

igni

ty d

rape

• 1

inst

ruct

ion

shee

t

AL

Rad

io c

ontr

ast

med

ia27

0am

idot

rizo

ate

inje

ctio

n14

0mg

to 4

20m

g

iodi

ne/m

l in

20m

l

271

bari

um s

ulfa

teaq

ueou

s su

spen

sion


EML FOR DHQs

DH

Qs

Sr.

#T

hera

peut

ic C

lass

Sr.

#G

ener

ic D

rug

Nam

eFo

rmS

tren

gth

27

2Io

hexo

lin

ject

ion

140m

g to

350

mg

iodi

ne/m

l in

5ml;

10m

l; 20

ml a

mpo

ules

.

AM

Den

tal m

ater

ials

273

NOTES

92 | ESSENTIAL MEDICINES LIST

NOTES

USAID | DELIVER PROJECT/IslamabadHouse No 253 C

Street 23Sector E 7

Islamabad, PakistanPhone: 92 .051 .2655425

Fax: 92 .051 .2655427Email: askdeliver@jsi .comInternet: deliver .jsi .com

Documents

ESSENTIAL - ION Graphic Design Works · standardized Essential Medicines List can meet end users’ requirements and help rationalizing the purchase and distribution of medicines,